# EDGAR Filing Document

**Accession Number:** 0001075415
**File Stem:** 0001075415-26-000024
**Filing Date:** 2026-5
**Character Count:** 173608
**Document Hash:** 1f733dd96b215973688696c2fe414a54
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001075415-26-000024.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0001075415-26-000024

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 75

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DIVERSIFIED HEALTHCARE TRUST
- **CENTRAL INDEX KEY:** 0001075415
- **STANDARD INDUSTRIAL CLASSIFICATION:** REAL ESTATE INVESTMENT TRUSTS [6798]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 043445278
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15319
- **FILM NUMBER:** 26938739

**BUSINESS ADDRESS:**
- **STREET 1:** C/O THE RMR GROUP
- **STREET 2:** TWO NEWTON PL., 255 WASH. ST., STE. 300
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02458
- **BUSINESS PHONE:** (617) 796-8350

**MAIL ADDRESS:**
- **STREET 1:** C/O THE RMR GROUP
- **STREET 2:** TWO NEWTON PL., 255 WASH. ST., STE. 300
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02458

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SENIOR HOUSING PROPERTIES TRUST
- **DATE OF NAME CHANGE:** 19981217

?xml version='1.0' encoding='ASCII'? dhc-20260331

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549** 

**FORM 10-Q** 

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended March 31, 2026**

**OR** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**Commission File Number 1-15319** 

**DIVERSIFIED HEALTHCARE TRUST** 

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Maryland** | **04-3445278** |
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |

---

**Two Newton Place, 255 Washington Street, Suite 300, Newton, MA 02458-1634** 

(Address of Principal Executive Offices) (Zip Code)

**617 - 796 - 8350** 

(Registrant's Telephone Number, Including Area Code)

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title Of Each Class** | **Trading Symbol(s)** | **Name Of Each Exchange On Which Registered** |
| Common Shares of Beneficial Interest | DHC | The Nasdaq Stock Market LLC |
| 5.625% Senior Notes due 2042 | DHCNI | The Nasdaq Stock Market LLC |
| 6.25% Senior Notes due 2046 | DHCNL | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of registrant's common shares outstanding as of April 30, 2026: 242,106,926

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

DIVERSIFIED HEALTHCARE TRUST

FORM 10-Q

March 31, 2026

INDEX

---

| | | |
|:---|:---|:---|
| | | **Page** |
| <u>[PART I](#icc333d3079ac4ecbb3cc50e20de4a4bc_10)</u> | <u>[Financial Information](#icc333d3079ac4ecbb3cc50e20de4a4bc_10)</u> | <u>[1](#icc333d3079ac4ecbb3cc50e20de4a4bc_10)</u> |
| <u>[Item 1.](#icc333d3079ac4ecbb3cc50e20de4a4bc_13)</u> | <u>[Financial Statements (unaudited)](#icc333d3079ac4ecbb3cc50e20de4a4bc_13)</u> | <u>[1](#icc333d3079ac4ecbb3cc50e20de4a4bc_13)</u> |
|  | <u>[Condensed Consolidated Balance Sheets —](#icc333d3079ac4ecbb3cc50e20de4a4bc_16)[March](#icc333d3079ac4ecbb3cc50e20de4a4bc_16)[31](#icc333d3079ac4ecbb3cc50e20de4a4bc_16)[, 2026](#icc333d3079ac4ecbb3cc50e20de4a4bc_16)[and December 31, 20](#icc333d3079ac4ecbb3cc50e20de4a4bc_16)[25](#icc333d3079ac4ecbb3cc50e20de4a4bc_16)</u> | <u>[1](#icc333d3079ac4ecbb3cc50e20de4a4bc_16)</u> |
|  | <u>[Condensed Consolidated Statements of Comprehensive Income (Loss) — Three](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)[Months Ended](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)[March 31](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)[, 202](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)[6](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)[and 202](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)[5](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)</u> | <u>[2](#icc333d3079ac4ecbb3cc50e20de4a4bc_19)</u> |
|  | <u>[Condensed Consolidated Statements of Shareholders' Equity — Three](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)[Months](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)[Ended](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)[March 31](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)[, 202](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)[6](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)[and 202](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)[5](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)</u> | <u>[3](#icc333d3079ac4ecbb3cc50e20de4a4bc_22)</u> |
|  | <u>[Condensed Consolidated Statements of Cash Flows —](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)[Three](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)[Months Ended](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)[March 31](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)[, 202](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)[6](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)[and 20](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)[25](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)</u> | <u>[4](#icc333d3079ac4ecbb3cc50e20de4a4bc_28)</u> |
|  | <u>[Notes to Condensed Consolidated Financial Statements](#icc333d3079ac4ecbb3cc50e20de4a4bc_31)</u> | <u>[6](#icc333d3079ac4ecbb3cc50e20de4a4bc_31)</u> |
| <u>[Item 2.](#icc333d3079ac4ecbb3cc50e20de4a4bc_94)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#icc333d3079ac4ecbb3cc50e20de4a4bc_94)</u> | <u>[20](#icc333d3079ac4ecbb3cc50e20de4a4bc_94)</u> |
| <u>[Item 3.](#icc333d3079ac4ecbb3cc50e20de4a4bc_112)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#icc333d3079ac4ecbb3cc50e20de4a4bc_112)</u> | <u>[34](#icc333d3079ac4ecbb3cc50e20de4a4bc_112)</u> |
| <u>[Item 4.](#icc333d3079ac4ecbb3cc50e20de4a4bc_115)</u> | <u>[Controls and Procedures](#icc333d3079ac4ecbb3cc50e20de4a4bc_115)</u> | <u>[35](#icc333d3079ac4ecbb3cc50e20de4a4bc_115)</u> |
|  | <u>[Warning Concerning Forward-Looking Statements](#icc333d3079ac4ecbb3cc50e20de4a4bc_118)</u> | <u>[36](#icc333d3079ac4ecbb3cc50e20de4a4bc_118)</u> |
|  | <u>[Statement Concerning Limited Liability](#icc333d3079ac4ecbb3cc50e20de4a4bc_121)</u> | <u>[38](#icc333d3079ac4ecbb3cc50e20de4a4bc_121)</u> |
| <u>[PART II](#icc333d3079ac4ecbb3cc50e20de4a4bc_124)</u> | <u>[Other Information](#icc333d3079ac4ecbb3cc50e20de4a4bc_124)</u> | <u>[39](#icc333d3079ac4ecbb3cc50e20de4a4bc_124)</u> |
| <u>[Item 1A.](#icc333d3079ac4ecbb3cc50e20de4a4bc_130)</u> | <u>[Risk Factors](#icc333d3079ac4ecbb3cc50e20de4a4bc_130)</u> | <u>[39](#icc333d3079ac4ecbb3cc50e20de4a4bc_130)</u> |
| <u>[Item 2.](#icc333d3079ac4ecbb3cc50e20de4a4bc_133)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#icc333d3079ac4ecbb3cc50e20de4a4bc_133)</u> | <u>[39](#icc333d3079ac4ecbb3cc50e20de4a4bc_133)</u> |
| <u>[Item 6.](#icc333d3079ac4ecbb3cc50e20de4a4bc_136)</u> | <u>[Exhibits](#icc333d3079ac4ecbb3cc50e20de4a4bc_136)</u> | <u>[39](#icc333d3079ac4ecbb3cc50e20de4a4bc_136)</u> |
|  | <u>[Signatures](#icc333d3079ac4ecbb3cc50e20de4a4bc_139)</u> | <u>[41](#icc333d3079ac4ecbb3cc50e20de4a4bc_139)</u> |

---

*References in this Quarterly Report on Form 10-Q to the Company, we, us or our include Diversified Healthcare Trust and its consolidated subsidiaries unless otherwise expressly stated or the context indicates otherwise.*

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**PART I. <u>Financial Information</u>**

**Item 1. Financial Statements.**

**DIVERSIFIED HEALTHCARE TRUST**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

***(dollars in thousands, except share data)***

***(unaudited)***

---

| | | |
|:---|:---|:---|
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| ASSETS |  |  |
| &nbsp;&nbsp;Real estate properties: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Land | $542645 | $542403 |
| &nbsp;&nbsp;&nbsp;&nbsp;Buildings and improvements | 5420371 | 5406403 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total real estate properties, gross | 5963016 | 5948806 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated depreciation | (2144130) | (2089906) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total real estate properties, net | 3818886 | 3858900 |
| &nbsp;&nbsp;Investments in unconsolidated joint ventures | 119622 | 120126 |
| &nbsp;&nbsp;Assets of properties held for sale |  | 23085 |
| &nbsp;&nbsp;Cash and cash equivalents | 121774 | 105407 |
| &nbsp;&nbsp;Restricted cash | 18078 | 16392 |
| &nbsp;&nbsp;Equity method investment |  | 27200 |
| &nbsp;&nbsp;Acquired real estate leases and other intangible assets, net | 19556 | 20663 |
| &nbsp;&nbsp;Other assets, net | 169636 | 189477 |
| &nbsp;&nbsp;Total assets | $4267552 | $4361250 |
| LIABILITIES AND SHAREHOLDERS' EQUITY |  |  |
| &nbsp;&nbsp;Secured revolving credit facility | $— | $— |
| &nbsp;&nbsp;Senior secured notes, net | 365516 | 365005 |
| &nbsp;&nbsp;Senior unsecured notes, net | 1581427 | 1580726 |
| &nbsp;&nbsp;Secured debt and finance leases, net | 454633 | 455093 |
| &nbsp;&nbsp;Liabilities of properties held for sale |  | 3426 |
| &nbsp;&nbsp;Accrued interest | 26078 | 30683 |
| &nbsp;&nbsp;Other liabilities | 219479 | 260749 |
| &nbsp;&nbsp;Total liabilities | 2647133 | 2695682 |
| Commitments and contingencies |  |  |
| Shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common shares of beneficial interest, $.01 par value: 300,000,000 shares authorized, 242,108,632 and 242,121,025 shares issued and outstanding, respectively | 2421 | 2421 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid in capital | 4623200 | 4622572 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cumulative net income | 1078862 | 1122137 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cumulative other comprehensive loss | (93) | (12) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cumulative distributions | (4083971) | (4081550) |
| &nbsp;&nbsp;Total shareholders' equity | 1620419 | 1665568 |
| &nbsp;&nbsp;Total liabilities and shareholders' equity | $4267552 | $4361250 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

***(amounts in thousands, except per share data)***

***(unaudited)***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Rental income | $49246 | $58558 |
| &nbsp;&nbsp;&nbsp;&nbsp;Residents fees and services | 317225 | 328306 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 366471 | 386864 |
| Expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property operating expenses | 290556 | 314326 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 62914 | 68325 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 14038 | 9000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition and certain other transaction related costs | 3693 | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of assets |  | 38472 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 371201 | 430147 |
| (Loss) gain on sale of real estate | (1207) | 110140 |
| Gain on insurance recoveries |  | 7522 |
| Interest and other income | 233 | 2099 |
| Interest expense (including net amortization of debt discounts, premiums and issuance costs of $2,329 and $26,087, respectively) | (37045) | (57831) |
| Loss on modification or early extinguishment of debt |  | (29071) |
| Loss before income taxes and equity in net earnings of investees | (42749) | (10424) |
| Income tax expense | (622) | (49) |
| Equity in net earnings of investees | 96 | 1487 |
| Net loss | $(43275) | $(8986) |
| Other comprehensive (loss) income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity in unrealized gains of an investee |  | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on derivative | (81) | (6) |
| Other comprehensive (loss) income | (81) | 21 |
| Comprehensive loss | $(43356) | $(8965) |
| Weighted average common shares outstanding (basic and diluted) | 240689 | 239957 |
| Net loss per common share (basic and diluted) | $(0.18) | $(0.04) |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

***(dollars in thousands)***

***(unaudited)***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| |<br>**Number of**<br>**Shares** |<br>**Common**<br>**Shares** |<br>**Additional**<br>**Paid in**<br>**Capital** |<br>**Cumulative**<br>**Net Income** | **Cumulative**<br>**Other**<br>**Comprehensive**<br>**(Loss) Income** |<br>**Cumulative**<br>**Distributions** |<br>**Total**<br>**Shareholders'**<br>**Equity** |
| Balance at December 31, 2025: | 242121025 | $2421 | $4622572 | $1122137 | $(12) | $(4081550) | $1665568 |
| &nbsp;&nbsp;Net loss |  |  |  | (43275) |  |  | (43275) |
| &nbsp;&nbsp;Other comprehensive income |  |  |  |  | (81) |  | (81) |
| &nbsp;&nbsp;Distributions |  |  |  |  |  | (2421) | (2421) |
| &nbsp;&nbsp;Share grants |  |  | 716 |  |  |  | 716 |
| &nbsp;&nbsp;Share repurchases | (12393) |  | (88) |  |  |  | (88) |
| Balance at March 31, 2026: | 242108632 | $2421 | $4623200 | $1078862 | $(93) | $(4083971) | $1620419 |
| Balance at December 31, 2024: | 241271703 | $2413 | $4620313 | $1408023 | $(17) | $(4071889) | $1958843 |
| &nbsp;&nbsp;Net loss |  |  |  | (8986) |  |  | (8986) |
| &nbsp;&nbsp;Other comprehensive income |  |  |  |  | 21 |  | 21 |
| &nbsp;&nbsp;Distributions |  |  |  |  |  | (2413) | (2413) |
| &nbsp;&nbsp;Share grants | 33582 |  | 605 |  |  |  | 605 |
| &nbsp;&nbsp;Share repurchases | (2035) |  | (6) |  |  |  | (6) |
| &nbsp;&nbsp;Share forfeitures | (35431) |  | (13) |  |  |  | (13) |
| Balance at March 31, 2025: | 241267819 | $2413 | $4620899 | $1399037 | $4 | $(4074302) | $1948051 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

***(dollars in thousands)***

***(unaudited)***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Net loss | $(43275) | $(8986) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 62914 | 68325 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net amortization of debt discounts, premiums and issuance costs | 2329 | 26087 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of accreted interest on senior secured notes |  | (34700) |
| &nbsp;&nbsp;&nbsp;&nbsp;Straight line rental income | (57) | (455) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired real estate leases and other intangible assets, net | 29 | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on modification or early extinguishment of debt |  | 29071 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of assets |  | 38472 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on sale of real estate | 1207 | (110140) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on insurance recoveries |  | (7522) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-cash adjustments, net | (226) | (351) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unconsolidated joint venture distributions | 600 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity in net earnings of investees | (96) | (1487) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred leasing costs, net | (1714) | (773) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 20766 | 6444 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | (4605) | (1733) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | (29530) | (5521) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | 8342 | (3243) |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Real estate improvements | (35166) | (39650) |
| &nbsp;&nbsp;Proceeds from sale of real estate, net | 21693 | 318235 |
| &nbsp;&nbsp;Equity method investment distributions | 27200 | 17000 |
| &nbsp;&nbsp;Contributions to unconsolidated joint ventures |  | (5800) |
| &nbsp;&nbsp;Proceeds from insurance recoveries |  | 1308 |
| &nbsp;&nbsp;Purchase of interest rate cap | (147) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | 13580 | 291093 |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Proceeds from mortgage notes payable |  | 140000 |
| &nbsp;&nbsp;Redemption of senior secured notes |  | (238555) |
| &nbsp;&nbsp;Repayment of other debt | (1187) | (840) |
| &nbsp;&nbsp;Early extinguishment of debt settled in cash |  | (25903) |
| &nbsp;&nbsp;Payment of debt issuance costs | (173) | (3332) |
| &nbsp;&nbsp;Repurchase of common shares | (88) | (6) |
| &nbsp;&nbsp;Distributions to shareholders | (2421) | (2413) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (3869) | (131049) |
| Increase in cash and cash equivalents and restricted cash | 18053 | 156801 |
| Cash and cash equivalents and restricted cash at beginning of period | 121799 | 149854 |
| Cash and cash equivalents and restricted cash at end of period | $139852 | $306655 |

---

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)**

***(dollars in thousands)***

***(unaudited)***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| SUPPLEMENTAL CASH FLOW INFORMATION: |  |  |
| &nbsp;&nbsp;Interest paid <sup>(1)</sup> | $39321 | $68177 |
| &nbsp;&nbsp;&nbsp;Income taxes paid | $— | $— |
| NON-CASH INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;Real estate improvements accrued, not paid | $5915 | $14383 |

---

(1)Includes $34,700 of accreted interest paid during the three months ended March 31, 2025 on our then outstanding senior secured notes due 2026.

Supplemental disclosure of cash and cash equivalents and restricted cash:

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within our condensed consolidated balance sheets to the amount shown in our condensed consolidated statements of cash flows:

---

| | | |
|:---|:---|:---|
| | **As of March 31,** | **As of March 31,** |
| | **2026** | **2025** |
| Cash and cash equivalents | $121774 | $302577 |
| Restricted cash <sup>(1)</sup> | 18078 | 4078 |
| &nbsp;&nbsp;Total cash and cash equivalents and restricted cash | $139852 | $306655 |

---

(1)Restricted cash consists of amounts escrowed for real estate taxes, insurance and capital expenditures at certain of our mortgaged properties.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

**<u>Note 1. Basis of Presentation</u>**

The accompanying condensed consolidated financial statements of Diversified Healthcare Trust and its subsidiaries, or DHC, we, us, or our, are unaudited. Certain information and disclosures required by U.S. generally accepted accounting principles, or GAAP, for complete financial statements have been condensed or omitted. We believe the disclosures made are adequate to make the information presented not misleading. However, the accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes contained in our Annual Report on Form 10-K for the year ended December 31, 2025, or our Annual Report.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of results for the interim period have been included. All intercompany transactions and balances with or among our consolidated subsidiaries have been eliminated. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year.

The preparation of these financial statements in conformity with GAAP requires us to make estimates and assumptions that affect reported amounts. Actual results could differ from those estimates. Significant estimates in our condensed consolidated financial statements include purchase price allocations, useful lives of fixed assets and impairments of real estate and intangible assets.

We have been, are currently and expect in the future to be involved in claims, lawsuits and regulatory and other governmental audits, investigations and proceedings arising in the ordinary course of our business. While the outcome of any litigation is inherently uncertain, we do not believe any currently pending litigation or proceedings will have a material adverse effect on our financial condition, results of operations or cash flows.

**<u>Note 2. Recent Accounting Pronouncements</u>**

In November 2024, the Financial Accounting Standards Board issued Accounting Standards Update No. 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statements Expenses*, or ASU No. 2024-03, which requires public entities to disclose specific expense categories such as employee compensation, depreciation and intangible asset amortization. These details must be presented in a tabular format in the notes to condensed consolidated financial statements for both interim and annual reporting periods. ASU 2024-03 is required to be applied prospectively but can be applied retrospectively, and is effective for the first annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact that ASU 2024-03 will have on our condensed consolidated financial statements.

**<u>Note 3. Real Estate and Other Investments</u>**

As of March 31, 2026, we owned 285 properties located in 33 states and Washington, D.C., and we owned an equity interest in each of two unconsolidated joint ventures that own medical office and life science properties located in five states.

*Acquisitions:*

In April 2026, we acquired two land parcels located in Lexington, Kentucky previously subject to our finance leases pursuant to our exercise of a purchase option for an aggregate purchase price of $14,500, excluding closing costs.

*Dispositions:*

The table below represents the sale prices, excluding closing costs, of our dispositions for the three months ended March 31, 2026. We do not believe these sales represent a strategic shift in our business. As a result, the results of operations

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

for these properties are included in continuing operations through the date of sale of such properties in our condensed consolidated statements of comprehensive income (loss).

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|<br>**Date of Sale** |<br>**State** |<br>**Type of Property** | **Number of**<br>**Properties** | **Number of**<br>**Units** |<br>**Sales Price** |<br>**Loss on Sale** |
| March 2026 | Various | Senior Living (SHOP) | 13 | 669 | $23000 | $(1207) |

---

*Impairment:*

We regularly evaluate our assets for indicators of impairment. Impairment indicators may include declining tenant or resident occupancy, weak or declining profitability from the property, decreasing tenant cash flows or liquidity, our decision to dispose of an asset before the end of its estimated useful life and legislative, market or industry changes that could permanently reduce the value of an asset. If indicators of impairment are present, we evaluate the carrying value of the affected assets by comparing it to the expected future undiscounted cash flows to be generated from those assets. The future cash flows are subjective and are based in part on assumptions regarding hold periods, market rents and terminal capitalization rates. If the sum of these expected future cash flows is less than the carrying value, we reduce the net carrying value of the asset to its estimated fair value. We did not record any impairment charges on our properties during the three months ended March 31, 2026.

*Investments and Capital Expenditures:*

The following is a summary of capital expenditures, development, redevelopment and other activities for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| SHOP fixed assets and capital improvements | $14193 | $21115 |
| Medical Office and Life Science Portfolio capital expenditures: |  |  |
| &nbsp;&nbsp;Lease related costs <sup>(1)</sup> | 3532 | 3847 |
| &nbsp;&nbsp;Building improvements <sup>(2)</sup> | 1003 | 1524 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal Medical Office and Life Science Portfolio | 4535 | 5371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total recurring capital expenditures | $18728 | $26486 |
| Development, redevelopment and other activities - SHOP <sup>(3)</sup> | $2981 | $5568 |
| Development, redevelopment and other activities - Medical Office and Life Science Portfolio <sup>(3)</sup> | 121 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total development, redevelopment and other activities | $3102 | $5568 |
| **Capital expenditures by segment:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;SHOP | $17174 | $26683 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical Office and Life Science Portfolio | 4656 | 5371 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total capital expenditures | $21830 | $32054 |

---

(1)Includes capital expenditures to improve tenants' space or amounts paid directly to tenants to improve their space and other leasing related costs, such as brokerage commissions and tenant inducements.

(2)Includes capital expenditures to replace obsolete building components that extend the useful life of existing assets or other improvements to increase the marketability of the property.

(3)Includes capital expenditures that reposition a property or result in change of use or new sources of revenue.

*Equity Method Investments in Unconsolidated Joint Ventures:*

We own a 10% equity interest in Seaport Innovation LLC, or the Seaport JV, an unconsolidated joint venture that owns one life science property located in Boston, Massachusetts totaling 1,134,479 square feet.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

We own a 20% equity interest in The LSMD Fund REIT LLC, or the LSMD JV, an unconsolidated joint venture that owns 10 medical office and life science properties located in five states totaling 1,068,763 square feet.

We account for the unconsolidated joint ventures using the equity method of accounting under the fair value option. We recognized changes in the fair value of our investments in the unconsolidated joint ventures of $96 and $1,138 during the three months ended March 31, 2026 and 2025, respectively. These amounts are included in equity in net earnings of investees in our condensed consolidated statements of comprehensive income (loss).

See Note 7 for further information regarding the valuation of our investment in these joint ventures.

*Equity Method Investment in AlerisLife:*

As of March 31, 2026, we owned approximately 34% of the outstanding common shares of AlerisLife Inc., or AlerisLife. We did not control the activities that were most significant to AlerisLife and, as a result, we accounted for our non-controlling interest in AlerisLife using the equity method of accounting. As of December 31, 2025, AlerisLife had ceased operations and was in the process of winding down its business. As of March 31, 2026 and December 31, 2025, our investment in AlerisLife had a carrying value of $0 and $27,200, respectively.

In connection with the wind-down of its business, on January 9, 2026, AlerisLife paid an aggregate cash dividend of $80,000 to its stockholders. Our pro rata share of this cash dividend was $27,200, thereby reducing the carrying value of our investment in AlerisLife to $0 as of March 31, 2026. We recognized no income or loss from our former equity method investment in AlerisLife for the three months ended March 31, 2026. We recognized income of $349 for the three months ended March 31, 2025, included in equity in net earnings of investees in our condensed consolidated statements of comprehensive income (loss). See Note 11 for more information regarding our former equity method investment in AlerisLife.

**<u>Note 4. Senior Living Community Management Agreements</u>**

Our managed senior living communities are operated by third parties pursuant to management agreements. Beginning in September 2025, we transitioned the management of 116 of our senior living communities previously managed by Five Star Senior Living, or Five Star, which was an operating division of AlerisLife, to seven different third party managers in connection with AlerisLife's sale of all of its assets and the wind-down of its business. As of December 31, 2025, we completed the transition of the management agreements for all of senior living communities previously managed by Five Star to these managers. In December 2025, we and Five Star terminated our amended and restated master management agreement, or the Master Management Agreement, as part of the wind-down of AlerisLife's business. We lease to our taxable REIT subsidiaries, or TRSs, nearly all of our senior living communities managed by third party managers.

We incurred management fees payable to Five Star of $0 and $11,234 for the three months ended March 31, 2026 and 2025, respectively. For the three months ended March 31, 2026 and 2025, $0 and $10,639, respectively, of the total management fees were expensed to property operating expenses in our condensed consolidated statements of comprehensive income (loss) and $0 and $595, respectively, were capitalized in our condensed consolidated balance sheets. The amounts capitalized are being depreciated over the estimated useful lives of the related capital assets.

*Our Senior Living Communities Managers.* As of March 31, 2026 and 2025, respectively, our managers managed 199 and 231 of our senior living communities, including closed communities.

We incurred management fees payable to our managers, other than Five Star, of $18,141 and $6,334 for the three months ended March 31, 2026 and 2025, respectively. Additionally, we incurred incentive management fees payable to certain of our operators of $0 and $351 for the three months ended March 31, 2026 and 2025, respectively. These amounts are included in property operating expenses in our condensed consolidated statements of comprehensive income (loss).

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

The following table presents residents fees and services revenue from all of our managed senior living communities disaggregated by the type of contract and payer:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Basic housing and support services | $278687 | $252772 |
| Private pay and other third party payer skilled nursing facility services | 20415 | 48254 |
| Medicare and Medicaid programs | 18123 | 27280 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total residents fees and services | $317225 | $328306 |

---

The following table provides a summary of our managers that manage a large concentration of our senior living communities as of March 31, 2026:

---

| | | |
|:---|:---|:---|
| |<br>**Number of**<br>**Communities** | **% of Gross**<br>**Real Estate**<br>**Properties** |
| Sinceri Senior Living | 38 | 30.7% |
| Discovery Senior Living | 44 | 23.8% |
| Tutera Senior Living | 18 | 8.9% |
| Phoenix Senior Living | 26 | 7.1% |
| Charter Senior Living | 30 | 7.0% |
| Remaining <sup>(1)</sup> | 43 | 22.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 199 | 100.0% |

---

(1)Includes closed senior living communities, if any.

**<u>Note 5. Leases</u>**

We are a lessor of medical office and life science properties, senior living communities and other healthcare related properties. Our leases provide our tenants with the contractual right to use and economically benefit from all of the premises demised under the leases; therefore, we have determined to evaluate our leases as lease arrangements.

Our leases provide for base rent payments and, in addition, may include variable payments. Rental income from operating leases, including any payments derived by index or market based indices, is recognized on a straight line basis over the lease term when we have determined that the collectability of substantially all of the lease payments is probable. Some of our leases have options to extend or terminate the lease exercisable at the option of our tenants, which are considered when determining the lease term.

We increased rental income to record revenue on a straight line basis by $57 and $455 for the three months ended March 31, 2026 and 2025, respectively. Rents receivable, excluding receivables related to our properties classified as held for sale, if any, include $62,220 and $62,163 of straight line rent receivables at March 31, 2026 and December 31, 2025, respectively, and are included in other assets, net in our condensed consolidated balance sheets.

We do not include in our measurement of our lease receivables certain variable payments, including changes in the index or market based indices after the inception of the lease, certain tenant reimbursements and other income until the specific events that trigger the variable payments have occurred. Such payments totaled $9,512 and $10,838 for the three months ended March 31, 2026 and 2025, respectively, of which tenant reimbursements totaled $9,473 and $10,423, respectively.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

*Right of Use Asset and Lease Liability:* For leases where we are the lessee, we recognize a right of use asset and a lease liability equal to the present value of the minimum lease payments, with rental payments being applied to the lease liability and the right of use asset being amortized over the term of the lease. The values of the right of use assets and related liabilities representing our future obligation under the respective lease arrangements for which we are the lessee were $15,636 and $16,016, respectively, as of March 31, 2026, and $16,537 and $16,921, respectively, as of December 31, 2025. The right of use assets and related lease liabilities are included within other assets, net and other liabilities, respectively, within our condensed consolidated balance sheets. In addition, we lease equipment at certain of our managed senior living communities. These leases are short term in nature, are cancelable with no fee or do not result in an annual expense in excess of our capitalization policy and, as a result, are not recorded on our condensed consolidated balance sheets.

**<u>Note 6. Indebtedness</u>**

At March 31, 2026 and December 31, 2025, our outstanding indebtedness consisted of the following:

*Senior Unsecured Notes:*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Principal Balance as of** | **Principal Balance as of** | | |
| | **March 31, 2026** | **December 31, 2025** |<br>**Coupon Rate** |<br>**Maturity** |
| Senior unsecured notes | $500000 | $500000 | 4.750% | February 2028 |
| Senior unsecured notes <sup>(1)</sup> | 500000 | 500000 | 4.375% | March 2031 |
| Senior unsecured notes | 350000 | 350000 | 5.625% | August 2042 |
| Senior unsecured notes | 250000 | 250000 | 6.250% | February 2046 |
| &nbsp;&nbsp;Total | 1600000 | 1600000 |  |  |
| &nbsp;&nbsp;Unamortized discount | (1585) | (1796) |  |  |
| &nbsp;&nbsp;Unamortized debt issuance costs | (16988) | (17478) |  |  |
| &nbsp;&nbsp;Senior unsecured notes, net | $1581427 | $1580726 |  |  |

---

(1)These notes are fully and unconditionally guaranteed, on a joint, several and unsecured basis, by all of our subsidiaries except certain excluded subsidiaries. The notes and related guarantees are effectively subordinated to all of our and the subsidiary guarantors' secured indebtedness, respectively, to the extent of the value of the applicable collateral, and are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes.

*Secured and Other Debt:*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | | | **Net Book Value** | **Net Book Value** |
| | | **Principal Balance as of** <sup>(1)</sup> | **Principal Balance as of** <sup>(1)</sup> | | | **of Collateral as of** | **of Collateral as of** |
| |<br>**Number of**<br>**Properties**<br>**Secured by** | **March 31,**<br>**2026** | **December 31,**<br>**2025** |<br>**Interest**<br>**Rate** |<br><br>**Maturity** | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Secured revolving credit facility | 14 | $— | $— | 6.28% | June 2029 | $322747 | $326565 |
| Senior secured notes <sup>(2)</sup>  | 36 | 375000 | 375000 | 7.25% | October 2030 | 398816 | 402797 |
| Floating rate mortgage loan <sup>(3)</sup> | 14 | 140000 | 140000 | 6.17% | March 2028 | 141531 | 142947 |
| Mortgage note | 4 | 63225 | 63499 | 6.57% | June 2030 | 134446 | 135772 |
| Mortgage note | 8 | 120000 | 120000 | 6.86% | June 2034 | 180471 | 182848 |
| Mortgage notes <sup>(4)</sup> | 7 | 108873 | 108873 | 6.22% | May 2035 | 146645 | 148477 |
| Mortgage notes <sup>(5)</sup> | 2 | 30284 | 30284 | 6.36% | June 2035 | 33979 | 34328 |
| Mortgage note | 1 | 5392 | 5847 | 6.44% | July 2043 | 12770 | 12893 |
| Finance Leases <sup>(6)</sup> | 2 | 155 | 613 | 7.70% | April 2026 | 19646 | 20128 |
| &nbsp;&nbsp;Total | 88 | 842929 | 844116 |  |  | $1391051 | $1406755 |
| &nbsp;&nbsp;Unamortized debt issuance costs <sup>(7)</sup> |  | (22780) | (24018) |  |  |  |  |
| &nbsp;&nbsp;Total secured and other debt, net |  | $820149 | $820098 |  |  |  |  |

---

(1)The principal balances are the amounts stated in the contracts. In accordance with GAAP, our carrying values and recorded interest expense may be different because of market conditions at the time we assumed certain of these debts.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

(2)These notes are fully and unconditionally guaranteed, on a joint, several and senior secured basis by certain of our subsidiaries that own 36 properties, or the 2030 Collateral Guarantors, and on a joint, several and unsecured basis, by all of our subsidiaries other than the 2030 Collateral Guarantors and certain excluded subsidiaries. These notes and the guarantees provided by the 2030 Collateral Guarantors are secured by a first priority lien on and security interest in 100% of the equity interests in each of the 2030 Collateral Guarantors. The unsecured guarantees related to these notes are effectively subordinated to all of the subsidiary guarantors' secured indebtedness to the extent of the value of the applicable collateral, and the notes and related guarantees are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes.

(3)This mortgage loan requires that interest be paid at an annual rate of one-month term secured overnight financing rate, or SOFR, plus a premium of 2.50% with interest-only payments through April 2027, and we have two six-month extension options of the interest-only period, subject to satisfaction of certain conditions. In connection with this mortgage loan, we have purchased an interest rate cap effective through March 2027 with a one-month term SOFR strike rate equal to 4.50% pursuant to the terms of the applicable loan agreement.

(4)These mortgage loans require interest-only payments through May 2030.

(5)These mortgage loans require interest-only payments through June 2028.

(6)In April 2026, we acquired the land parcels at two senior living communities previously subject to our finance leases pursuant to our exercise of a purchase option for an aggregate purchase price of $14,500, excluding closing costs.

(7)Excludes unamortized debt issuance costs for our revolving credit facility as these costs are included in other assets, net in our condensed consolidated balance sheets.

As of March 31, 2026, all $500,000 of our 4.375% senior notes due 2031 were fully and unconditionally guaranteed, on a joint, several and unsecured basis, by all of our subsidiaries except certain excluded subsidiaries. The notes and related guarantees are effectively subordinated to all of our and the subsidiary guarantors' secured indebtedness, respectively, to the extent of the value of the applicable collateral, and the notes and related guarantees are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes. Our remaining $1,100,000 of senior unsecured notes do not have the benefit of any guarantees as of March 31, 2026.

Our revolving credit facility is available for general business purposes, including acquisitions. We can borrow, repay and reborrow funds available under our revolving credit facility, and no principal repayments are due, until maturity. Availability of borrowings under the agreement governing our revolving credit facility, or our credit agreement, is subject to satisfying certain financial covenants and other credit facility conditions. Our revolving credit facility matures in June 2029 and we have two six-month extension options for the maturity date of the facility, subject to satisfaction of certain conditions and payment of an extension fee.

Interest payable on borrowings under our revolving credit facility is based on daily SOFR plus a premium of 2.50% to 3.00%, depending on our net leverage ratio, as defined in our credit agreement, which was 2.50% as of March 31, 2026. We also pay an unused commitment fee of 25 to 35 basis points per annum based on amounts outstanding under our revolving credit facility. As of March 31, 2026, the annual interest rate payable on borrowings under our revolving credit facility was 6.28%. As of March 31, 2026 and April 30, 2026, we had no borrowings under our revolving credit facility and $150,000 available for borrowings.

Interest on our senior unsecured notes and our 7.25% senior secured notes due 2030 is payable either semi-annually or quarterly in arrears; however, no principal repayments are due until maturity. Our mortgage loan maturing in June 2034 requires monthly interest payments and no principal payment is due until maturity, while our mortgage loans maturing in March 2028, May 2035 and June 2035 require monthly interest payments and no principal payment is due for a specified amount of time. Our mortgage loans maturing in June 2030 and July 2043 require monthly principal and interest payments. Payments under our finance leases were due monthly. We included amortization of finance lease assets in depreciation and amortization expense.

Our credit agreement, our mortgage loan agreements and our senior notes indentures and their supplements provide for acceleration of payment of all amounts outstanding upon the occurrence and continuation of certain events of default. Our credit agreement and our senior notes indentures and their supplements also contain covenants that restrict our ability to incur debts, including debts secured by mortgages on our properties, in excess of calculated amounts and require us to maintain various financial ratios. Borrowings under our revolving credit facility are subject to satisfying certain financial covenants and other credit facility conditions. We believe we were in compliance with the terms and conditions of our debt agreements as of March 31, 2026.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

Required principal payments due in the next five years and thereafter, excluding extension options, on all of our outstanding debt as of March 31, 2026, were as follows:

---

| | |
|:---|:---|
| | **Principal Payment** |
| 2026 | $1076 |
| 2027 | 2260 |
| 2028 | 640635 |
| 2029 | 1867 |
| 2030 | 435135 |
| Thereafter | 1361956 |
| &nbsp;&nbsp;Total | $2442929 |

---

**<u>Note 7. Fair Value of Assets and Liabilities</u>**

The table below presents certain of our assets that are measured on a recurring basis at fair value as of March 31, 2026 and December 31, 2025, categorized by the level of inputs, as defined in the fair value hierarchy under GAAP, used in the valuation of each asset:

---

| | | | | |
|:---|:---|:---|:---|:---|
| |<br><br>**Total** | **Quoted Prices in**<br>**Active Markets for**<br>**Identical Assets**<br>**(Level 1)** | **Significant Other**<br>**Observable**<br>**Inputs**<br>**(Level 2)** | **Significant**<br>**Unobservable**<br>**Inputs**<br>**(Level 3)** |
| **As of March 31, 2026** | | | | |
| &nbsp;&nbsp;Interest rate cap <sup>(1)</sup> | $52 | $— | $52 | $— |
| &nbsp;&nbsp;Investment in Seaport JV <sup>(2)</sup> | $73217 | $— | $— | $73217 |
| &nbsp;&nbsp;Investment in LSMD JV <sup>(2)</sup> | $46405 | $— | $— | $46405 |
| **As of December 31, 2025** |  |  |  |  |
| &nbsp;&nbsp;Interest rate cap <sup>(1)</sup> | $— | $— | $— | $— |
| &nbsp;&nbsp;Investment in Seaport JV <sup>(2)</sup> | $73471 | $— | $— | $73471 |
| &nbsp;&nbsp;Investment in LSMD JV <sup>(2)</sup> | $46655 | $— | $— | $46655 |

---

(1)The fair values of our interest rate cap derivatives are based on prevailing market prices in secondary markets for similar derivative contracts as of the measurement date.

(2)The assumptions we made in the fair value analysis are based on the location, type and nature of each property, and current and anticipated market conditions.

The discount rates, exit capitalization rates and holding periods used to determine the fair value of our investments in the unconsolidated joint ventures' significant unobservable inputs are shown in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| |<br>**Valuation**<br>**Technique** |<br>**Discount**<br>**Rates** | **Exit**<br>**Capitalization**<br>**Rates** |<br>**Holding**<br>**Periods** |
| **As of March 31, 2026** | | | | |
| Investment in Seaport JV | Discounted cash flow | 7.00% | 6.00% | 10 years |
| Investment in LSMD JV | Discounted cash flow | 6.25% - 8.75% | 5.25% - 8.00% | 10 years |
| **As of December 31, 2025** |  |  |  |  |
| Investment in Seaport JV | Discounted cash flow | 7.00% | 6.00% | 10 years |
| Investment in LSMD JV | Discounted cash flow | 6.25% - 8.75% | 5.25% - 8.00% | 10 - 12 years |

---

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

The table below presents a summary of the changes in fair value for our investments in the unconsolidated joint ventures:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Beginning balance | $120126 | $126859 |
| Equity in earnings of unconsolidated joint ventures | 96 | 1138 |
| Contributions to unconsolidated joint ventures |  | 5800 |
| Distributions from unconsolidated joint ventures | (600) |  |
| Ending balance | $119622 | $133797 |

---

In addition to the assets described in the tables above, our financial instruments at March 31, 2026 and December 31, 2025 included cash and cash equivalents, restricted cash, certain other assets, our revolving credit facility, senior unsecured notes, senior secured notes, secured debt and finance leases and certain other unsecured obligations and liabilities. The fair values of these financial instruments approximated their carrying values in our condensed consolidated financial statements as of such dates, except as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of March 31, 2026** | **As of March 31, 2026** | **As of December 31, 2025** | **As of December 31, 2025** |
| | **Carrying**<br>**Value** <sup>(1)</sup> | **Estimated**<br>**Fair Value** | **Carrying**<br>**Value** <sup>(1)</sup> | **Estimated**<br>**Fair Value** |
| Senior unsecured notes, 4.750% coupon rate, due 2028 | $497608 | $480465 | $497290 | $482635 |
| Senior secured notes, 7.250% coupon rate, due 2030 | 365516 | 378221 | 365005 | 383434 |
| Senior unsecured notes, 4.375% coupon rate, due 2031 | 495775 | 444350 | 495561 | 440000 |
| Senior unsecured notes, 5.625% coupon rate, due 2042 | 343778 | 226520 | 343683 | 224140 |
| Senior unsecured notes, 6.250% coupon rate, due 2046 | 244266 | 171200 | 244192 | 175000 |
| Secured debt and finance leases | 454633 | 480922 | 455093 | 484932 |
| &nbsp;&nbsp;Total | $2401576 | $2181678 | $2400824 | $2190141 |

---

(1)Includes unamortized net discounts, premiums and debt issuance costs, if any.

We estimated the fair values of our two issuances of senior unsecured notes due 2042 and 2046 based on the closing price on The Nasdaq Stock Market LLC, or Nasdaq, as of March 31, 2026 and December 31, 2025 (Level 1 inputs as defined in the fair value hierarchy under GAAP). We estimated the fair values of our two issuances of senior unsecured notes due 2028 and 2031 and our issuance of senior secured notes 2030 using an average of the bid and ask price on Nasdaq on or about March 31, 2026 and December 31, 2025 (Level 2 inputs as defined in the fair value hierarchy under GAAP). We estimated the fair values of our secured debts by using discounted cash flows analyses and currently prevailing market terms as of the measurement date (Level 3 inputs as defined in the fair value hierarchy under GAAP). Because Level 3 inputs are unobservable, our estimated fair values may differ materially from the actual fair values.

**<u>Note 8. Shareholders' Equity</u>**

*Common Share Purchases:*

During the three months ended March 31, 2026, we purchased an aggregate of 12,393 of our common shares, valued at a share price of $7.15, from certain former employees of The RMR Group LLC, or RMR, in satisfaction of tax withholding and payment obligations in connection with the vesting of prior awards of our common shares. We withheld and purchased these common shares at their fair market value based upon the trading price of our common shares at the close of trading on Nasdaq on the purchase date.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

*Distributions:*

During the three months ended March 31, 2026, we declared and paid a quarterly distribution to common shareholders as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Declaration Date** | **Record Date** | **Payment Date** | **Distribution Per Share** | **Total Distributions** |
| January 15, 2026 | January 26, 2026 | February 19, 2026 | $0.01 | $2421 |

---

On April 9, 2026, we declared a quarterly distribution to common shareholders of record on April 21, 2026 of $0.01 per share, or approximately $2,421. We expect to pay this distribution on or about May 14, 2026 using cash on hand.

**<u>Note 9. Segment Reporting</u>**

Our operating segments are based on our internal reporting structure and property type and are aligned with how our Chief Operating Decision Maker, or the CODM, reviews the operating results to allocate resources and assess segment performance. The CODM is our President and Chief Executive Officer. Our two reportable segments are SHOP and Medical Office and Life Science Portfolio. Our SHOP segment consists of managed senior living communities that provide short term and long term residential living and, in some instances, care and other services for residents where we pay fees to managers to operate the communities on our behalf. Our Medical Office and Life Science Portfolio segment primarily consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties primarily leased to biotech laboratories and other similar tenants. The significant expense categories and amounts presented below align with the segment-level information that is regularly provided to our CODM. The CODM reviews operating and financial results, including net income (loss) and its components, to assess performance, allocate resources and guide strategic decisions. For further information regarding the accounting policies of our reportable segments, see Note 2 to our consolidated financial statements included in Part IV, Item 15 of our Annual Report.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

The tables below present information about our segments:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| |<br><br>**SHOP**  | **Medical Office**<br>**and**<br>**Life Science**<br>**Portfolio** |<br><br>**Total** |<br><br>**SHOP** | **Medical Office**<br>**and**<br>**Life Science**<br>**Portfolio** |<br><br>**Total** |
| Revenues: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Rental income | $— | $41895 | $41895 | $— | $49763 | $49763 |
| &nbsp;&nbsp;&nbsp;&nbsp;Residents fees and services | 317225 |  | 317225 | 328306 |  | 328306 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 317225 | 41895 | 359120 | 328306 | 49763 | 378069 |
| &nbsp;&nbsp;Reconciliation of revenue: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other revenue <sup>(1)</sup> |  |  | 7351 |  |  | 8795 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues |  |  | 366471 |  |  | 386864 |
| Less: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Senior living labor and benefits | 151262 |  | 151262 | 162404 |  | 162404 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dietary | 19389 |  | 19389 | 20246 |  | 20246 |
| &nbsp;&nbsp;&nbsp;&nbsp;Utilities | 19191 | 2763 | 21954 | 19578 | 3602 | 23180 |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate taxes | 11296 | 4508 | 15804 | 12070 | 5834 | 17904 |
| &nbsp;&nbsp;&nbsp;&nbsp;Insurance | 10396 | 440 | 10836 | 10313 | 621 | 10934 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating expenses <sup>(2)</sup> | 62065 | 9120 | 71185 | 66867 | 12850 | 79717 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 6557 | 2231 | 8788 | 66 | 2253 | 2319 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 46865 | 13519 | 60384 | 48635 | 17321 | 65956 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment items <sup>(3)</sup> | 1260 | (150) | 1110 | (8786) | 26018 | 17232 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment (loss) income | (11056) | 9464 | (1592) | (3087) | (18736) | (21823) |
| Reconciliation of segment (loss) income: | Reconciliation of segment (loss) income: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income <sup>(1)</sup> |  |  | 4694 |  |  | 6485 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative |  |  | (14038) |  |  | (9000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition and certain other transaction related costs |  |  | (3693) |  |  | (24) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of real estate |  |  |  |  |  | 97560 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and other income |  |  | 233 |  |  | 2099 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  |  | (28257) |  |  | (55512) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on modification or early extinguishment of debt |  |  |  |  |  | (29071) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense |  |  | (622) |  |  | (49) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity in net earnings of an investee |  |  |  |  |  | 349 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss |  |  | $(43275) |  |  | $(8986) |

---

(1)Revenue and net income from our triple net leased wellness centers and senior living communities that are leased to third party operators, which we do not consider to be sufficiently material to constitute a separate reportable segment.

(2)Other operating expenses for each reportable segment include expenses such as management fees, repairs and maintenance, cleaning and other costs incurred in connection with the operation of our properties.

(3)Other segment items for each reportable segment include impairment of assets, gain (loss) on sale of real estate, gain (loss) on modification or early extinguishment of debt, equity in net earnings (losses) of investees, interest and other income and gain on insurance recoveries, as applicable.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| Assets: <sup>(1)</sup> | **March 31, 2026** | **December 31, 2025** |
| SHOP | $2774342 | $2867025 |
| Medical Office and Life Science Portfolio | 1185976 | 1192731 |
| All Other | 307234 | 301494 |
| &nbsp;&nbsp;Total assets | $4267552 | $4361250 |

---

(1)See Note 3 for further information regarding additions to long-lived assets.

**<u>Note 10. Business and Property Management Agreements with RMR</u>**

We have no employees. The personnel and various services we require to operate our business are provided to us by RMR. We have two agreements with RMR to provide management services to us: (1) a business management agreement, which relates to our business generally; and (2) a property management agreement, which relates to the property level operations of many of our properties, including our medical office and life science properties, and major renovation or repositioning activities at our senior living communities that we may request RMR to manage from time to time. See Note 11 for further information regarding our relationship, agreements and transactions with RMR.

*Business Management Agreements with RMR.* Pursuant to our business management agreement and in accordance with GAAP, we accrued estimated incentive management fees during the three months ended March 31, 2026 and 2025. The actual amount of incentive management fees incurred for 2026, if any, will be based on our common share total return, as defined in our business management agreement, for the three-year period ending December 31, 2026, and will be payable to RMR in January 2027. We incurred a $17,905 incentive management fee pursuant to our business management agreement for the year ended December 31, 2025. We paid this incentive management fee to RMR in January 2026.

*Expense Reimbursement.* We are generally responsible for all our operating expenses, including certain expenses incurred or arranged by RMR on our behalf. We are generally not responsible for payment of RMR's employment, office or administrative expenses incurred to provide management services to us, except for the employment and related expenses of RMR's employees assigned to work exclusively or partly at our properties, our share of the wages, benefits and other related costs of RMR's centralized accounting personnel, our share of RMR's costs for providing our internal audit function, or as otherwise agreed. Our property level operating expenses are generally incorporated into the rents charged to our tenants, including certain payroll and related costs incurred by RMR.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

For the three months ended March 31, 2026 and 2025, the business management fees, incentive management fees, property management fees and construction supervision fees and expense reimbursements recognized in our condensed consolidated financial statements were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| |<br>**Financial Statement Line Item** | **2026** | **2025** |
| **Pursuant to business management agreement:** | **Pursuant to business management agreement:** |  |  |
| &nbsp;&nbsp;Business management fees | General and administrative expenses <sup>(1)</sup> | $4277 | $3809 |
| &nbsp;&nbsp;Incentive management fees | General and administrative expenses | 6628 | 2407 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total |  | $10905 | $6216 |
| **Pursuant to property management agreement** <sup>(2)</sup>**:** | **Pursuant to property management agreement** <sup>(2)</sup>**:** |  |  |
| &nbsp;&nbsp;Property management fees | Property operating expenses | $1014 | $1264 |
| &nbsp;&nbsp;Construction supervision fees | Building and improvements <sup>(3)</sup> | 325 | 226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total |  | $1339 | $1490 |
| **Expense Reimbursement:** |  |  |  |
| &nbsp;&nbsp;Other expenses | General and administrative expenses | $44 | $50 |
| &nbsp;&nbsp;Property level expenses | Property operating expenses | 2317 | 3741 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total |  | $2361 | $3791 |

---

(1)The net business management fees we recognized for the three months ended March 31, 2026 and 2025 reflect a reduction of $744 for each of those periods for the amortization of the liability we recorded in connection with our former investment in The RMR Group Inc., or RMR Inc., as further described in Note 11.

(2)The net property management and construction supervision fees we recognized for the three months ended March 31, 2026 and 2025 reflect a reduction of $199 for each of those periods for the amortization of the liability we recorded in connection with our former investment in RMR Inc., as further described in Note 11.

(3)Amounts capitalized as building improvements are depreciated over the estimated useful lives of the related capital assets.

*Management Agreements between our Joint Ventures and RMR.* We have two separate joint venture arrangements with third party institutional investors, the Seaport JV and the LSMD JV. RMR provides management services to both of these joint ventures. Our joint ventures are not our consolidated subsidiaries and, as a result, we are not obligated to pay management fees to RMR under our management agreements with RMR for the services it provides regarding the joint ventures.

**<u>Note 11. Related Person Transactions</u>**

We have relationships and historical and continuing transactions with RMR, RMR Inc., AlerisLife (including Five Star) and others related to them, including other companies to which RMR or its subsidiaries provide management services and some of which have trustees, directors or officers who are also our Trustees or officers. RMR is a majority owned subsidiary of RMR Inc. The Chair of our Board of Trustees and one of our Managing Trustees, Adam D. Portnoy, is the sole trustee, an officer and the controlling shareholder of ABP Trust, which is the controlling shareholder of RMR Inc., chair of the board of directors, a managing director and the president and chief executive officer of RMR Inc., an officer and employee of RMR and the sole director of AlerisLife. Christopher J. Bilotto, our other Managing Trustee and President and Chief Executive Officer is also an executive of RMR Inc., Matthew C. Brown, our Chief Financial Officer and Treasurer, is also an executive vice president and the chief financial officer and treasurer of RMR Inc. and an officer of ABP Trust, and each of our officers is also an officer and employee of RMR. Some of our Independent Trustees also serve as independent trustees of other public companies to which RMR or its subsidiaries provide management services. Adam D. Portnoy serves as the chair of the board and as a managing trustee of these companies. Other officers of RMR, including Mr. Bilotto, Mr. Brown and certain of our officers, serve as managing trustees, or officers of certain of these companies. In addition, officers of RMR and RMR Inc. serve as our officers and officers of other companies to which RMR or its subsidiaries provide management services. As of March 31, 2026, ABP Trust and Adam D. Portnoy owned 9.8% of our outstanding common shares.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

*AlerisLife.* As of March 31, 2026, we owned approximately 34% of the outstanding AlerisLife common shares and ABP Trust owned the approximate remaining 66% of AlerisLife. As of December 31, 2025, we completed the transition of the management agreements for all of the senior living communities previously managed by Five Star to third party managers and terminated the Master Management Agreement with Five Star.

On February 14, 2025 and July 15, 2025, AlerisLife paid aggregate cash dividends of $50,000 and $10,000, respectively, to its stockholders, and our pro rata share of these cash dividends was $17,000 and $3,400, respectively. In connection with the wind-down of its business, on January 9, 2026, AlerisLife paid an aggregate cash dividend of $80,000 to its stockholders, and our pro rata share of this cash dividend was $27,200.

See Note 4 for further information regarding our relationships, agreements and transactions with AlerisLife (including Five Star) and Note 3 for further information regarding our investment in AlerisLife.

*Our Joint Ventures.* In connection with our entering into the LSMD JV in January 2022, we paid mortgage escrow amounts and closing costs that were payable by that joint venture. The remaining costs totaled $3,965 as of March 31, 2026 and are included in other assets, net, in our condensed consolidated balance sheet. RMR provides management services to each of the Seaport JV and the LSMD JV. See Note 10 for further information regarding those management agreements with RMR.

*Our Manager, RMR.* We have two agreements with RMR to provide management services to us. See Note 10 for further information regarding our management agreements with RMR.

*Leases with RMR.* We lease office space to RMR in certain of our properties for RMR's property management offices. We recognized rental income from RMR for leased office space of $108 and $107 for the three months ended March 31, 2026 and 2025, respectively.

For further information about these and other such relationships and certain other related person transactions, see our Annual Report.

**<u>Note 12. Derivatives and Hedging Activities</u>**

*Risk Management Objective of Using Derivatives*

We are exposed to certain risks relating to our ongoing business operations, including the impact of changes in interest rates. The only risk currently managed by us using derivative instruments is our interest rate risk. As required under the applicable loan agreement, we have an interest rate cap agreement to manage our interest rate risk exposure on our $140,000 floating rate mortgage loan secured by 14 senior living communities with interest payable at a rate equal to one-month term SOFR plus a premium of 2.50%. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, we only enter into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which we or our related parties may also have other financial relationships. We do not anticipate that any of the counterparties will fail to meet their obligations.

*Cash Flow Hedges of Interest Rate Risk*

Our interest rate cap agreement is designated as a cash flow hedge of interest rate risk and is measured on a recurring basis at fair value. The following table summarizes the terms of our outstanding interest rate cap agreement as of March 31, 2026 and December 31, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | | | **Fair Value as of** | **Fair Value as of** |
| **Balance**<br>**Sheet**<br>**Line Item** |<br>**Underlying**<br>**Instrument** |<br>**Maturity**<br>**Date** |<br>**Strike**<br>**Rate** |<br>**Notional**<br>**Amount** | **March 31, 2026** | **December 31, 2025** |
| Other assets, net | Floating rate mortgage loan | 3/31/2028 | 4.50% | $140000 | $52 | $— |

---

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**DIVERSIFIED HEALTHCARE TRUST**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***(dollar amounts in thousands, except per share data or as otherwise stated)***

Interest rate caps designated as cash flow hedges involve the receipt of variable amounts from a counterparty if interest rates rise above the strike rate on the contract in exchange for an up-front premium. For derivatives designated and qualifying as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in cumulative other comprehensive income (loss) and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Gains and losses on the derivative representing hedge components excluded from the assessment of effectiveness are recognized over the life of the hedge on a systematic and rational basis, as documented at hedge inception in accordance with our accounting policy election. The earnings recognition of excluded components is presented in interest expense. Amounts reported in cumulative other comprehensive income (loss) related to derivatives will be reclassified to interest expense as interest payments are made, if any, on our applicable debt.

The following table summarizes the activity related to our cash flow hedges within cumulative other comprehensive income (loss) for the periods shown:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Amount of loss recognized on derivative in other comprehensive income (loss) | $(95) | $(6) |
| Amount of loss reclassified from cumulative other comprehensive income (loss) into interest expense | $(14) | $— |
| Total amount of interest expense presented in the condensed consolidated statements of comprehensive income (loss) | $(37045) | $(57831) |

---

See Notes 6 and 7 for further information regarding the debt our interest rate cap is related to and the fair value of our interest rate cap.

**<u>Note 13. Income Taxes</u>**

We have elected to be taxed as a real estate investment trust, or REIT, under the Internal Revenue Code of 1986, as amended, and, as such, are generally not subject to federal and most state income taxation on our operating income provided we distribute our taxable income to our shareholders and meet certain organization and operating requirements. We do, however, lease our managed senior living communities to our wholly owned TRSs that, unlike most of our subsidiaries, file a separate consolidated federal corporate income tax return and are subject to federal and state income taxes. Our consolidated income tax provision includes the income tax provision related to the operations of our TRSs and certain state income taxes we incur despite our taxation as a REIT. Our current income tax expense (or benefit) fluctuates from period to period based primarily on the timing of our income, including gains on the disposition of properties or losses in a particular quarter. For the three months ended March 31, 2026 and 2025, we recognized income tax expense of $622 and $49, respectively.

**<u>Note 14. Weighted Average Common Share</u><u>s</u>**

We calculate basic earnings per common share using the two class method. We calculate diluted earnings per share using the more dilutive of the two class method or the treasury stock method. Unvested share awards and other potentially dilutive common shares, together with the related impact on earnings, are considered when calculating diluted earnings per share.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussion should be read in conjunction with our condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and with our Annual Report.

**OVERVIEW**

We are a REIT organized under Maryland law that primarily owns senior living communities, medical office and life science properties and other healthcare related properties throughout the United States. As of March 31, 2026, we owned 285 properties located in 33 states and Washington, D.C. As of March 31, 2026, we owned an equity interest in each of the Seaport JV and the LSMD JV that own medical office and life science properties located in five states with an aggregate of approximately 2.2 million rentable square feet that were 99% leased with an average (by annualized rental income) remaining lease term of 13.9 years.

We are encouraged by positive trends, including increases in rates, margins and occupancy in our SHOP segment. Additionally, we expect that favorable supply and demand dynamics in the senior living industry will enable our managers to continue to grow occupancy and drive positive performance. While certain costs, primarily labor, insurance and food costs, have increased, we expect these cost increases to moderate, which will provide our managers the opportunity to increase revenue in excess of increases in costs, resulting in improving returns to us.

In an effort to optimize performance, our asset management team reviews the results of each of our senior living communities and our operators, taking into account various factors such as performance metric benchmarks, location and other relevant data points. This comprehensive review process ensures that our decisions are data-driven and strategically aligned with our overall objectives. As a result of these reviews, our strategy to drive positive performance includes analyzing non-performing communities for potential disposition or transition to different operators.

We are closely monitoring the impacts of the current economic and market conditions on all aspects of our business, including, but not limited to, uncertainties surrounding interest rates and inflation, volatility in the public debt and equity markets, global geopolitical hostilities and tensions, any U.S. government shutdown, economic uncertainties and tariffs, labor market conditions and changes in real estate utilization. We expect to experience continued variability in labor, insurance and food costs in our SHOP segment. Inflationary pressures in the United States, as well as global geopolitical instability and tensions, have given rise to uncertainty regarding potential disruptions in the financial markets. Continued or intensified disruptions in the financial markets could adversely affect our financial condition and that of our managers, operators and tenants, could adversely impact the ability or willingness of our managers, operators, tenants or residents to pay amounts owed to us, could impair our ability to effectively deploy our capital or realize our target returns on our investments, may restrict our access to, and would likely increase, our cost of capital, and may cause the values of our properties and of our securities to decline.

For further information and risks relating to these economic uncertainties and their impact on our business and financial condition, see Part I, Item 1, "Business" and Part I, Item 1A, "Risk Factors" in our Annual Report.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

***Portfolio Overview***

The following tables present an overview of our portfolio as of and for the three months ended March 31, 2026 (dollars in thousands, except average monthly rate):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Number of Units** | **Number of Units** | | | |
| | | **or** | **or** | | | |
| |<br>**Number of**<br>**Properties** | **Square Feet** | **Square Feet** | **Gross**<br>**Book Value**<br>**of Real Estate**<br>**Assets** <sup>(1)</sup> |<br><br>**NOI** <sup>(2)</sup> |<br><br>**% of NOI** <sup>(2)</sup> |
| SHOP | 199 | 22573 | units | $4375739 | $43626 | 57.5% |
| Medical Office and Life Science Portfolio | 67 | 5558089 | sq. ft. | 1491588 | 25064 | 33.0% |
| Triple net leased senior living communities | 9 | 1328 | units | 155162 | 3440 | 4.5% |
| Wellness centers | 10 | 812246 | sq. ft. | 208110 | 3785 | 5.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 285 |  |  | $6230599 | $75915 | 100.0% |

---

(1)Represents gross book value of real estate assets at cost plus certain acquisition costs, before depreciation and purchase price allocations and less impairment write downs, if any.

(2)We calculate our net operating income, or NOI, on a consolidated basis and by reportable segment. Our definition of NOI and our reconciliation of net income (loss) to NOI are included below under the heading "Non-GAAP Financial Measures."

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Comparable Properties** <sup>(1)</sup> | **Comparable Properties** <sup>(1)</sup> | **Comparable Properties** <sup>(1)</sup> | **Comparable Properties** <sup>(1)</sup> | **All Properties** | **All Properties** | **All Properties** | **All Properties** |
| | **As of and for the** | **As of and for the** | **As of and for the** | **As of and for the** | **As of and for the** | **As of and for the** | **As of and for the** | **As of and for the** |
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** | **2026** | **2026** | **2025** | **2025** |
| **<u>SHOP</u>** |  |  |  |  |  |  |  |  |
| Total properties | 184 |  | 184 |  | 199 |  | 231 |  |
| Number of units | 21226 |  | 21226 |  | 22573 |  | 25005 |  |
| Occupancy | 82.4 | % | 81.3 | % | 81.7 | % | 80.2 | % |
| Average monthly rate <sup>(2)</sup> | $5656 |  | $5341 |  | $5613 |  | $5413 |  |
| **<u>Medical Office and Life Science Portfolio</u>** <sup>(3)</sup> |  |  |  |  |  |  |  |  |
| Total properties | 65 |  | 65 |  | 67 |  | 93 |  |
| Total square feet | 5349272 |  | 5349272 |  | 5558089 |  | 7619667 |  |
| Occupancy | 95.3 | % | 94.7 | % | 91.8 | % | 80.6 | % |
| **<u>All Other</u>** |  |  |  |  |  |  |  |  |
| ***Total properties:*** |  |  |  |  |  |  |  |  |
| Triple net leased senior living communities | 8 |  | 8 |  | 9 |  | 9 |  |
| Wellness centers | 10 |  | 10 |  | 10 |  | 10 |  |
| ***Rent coverage:*** <sup>(4)</sup> |  |  |  |  |  |  |  |  |
| Triple net leased senior living communities | 1.84 | x | 1.73 | x | 1.84 | x | 1.73 | x |
| Wellness centers | 3.09 | x | 2.51 | x | 3.09 | x | 2.51 | x |
| Weighted average | 2.49 | x | 2.12 | x | 2.49 | x | 2.12 | x |

---

(1)Consists of properties that we have owned and are in service and which have been reported in the same segment and leased to the same operator continuously since January 1, 2025; excludes properties classified as held for sale, planned for sale, closed or out of service, if any, and medical office and life science properties owned by unconsolidated joint ventures in which we own an equity interest. Properties are included in same property once stabilized for the full period in both comparison periods presented.

(2)Average monthly rate reflects the average monthly residents fees and services per occupied unit for the period presented. The average monthly rate is calculated based on the actual number of days during the period.

(3)Medical office and life science property occupancy data includes (i) out of service assets undergoing redevelopment, (ii) space which is leased but is not occupied or is being offered for sublease by tenants and (iii) space being fitted out for occupancy.

(4)All tenant operating data presented are based upon the operating results provided by our tenants for the most recent prior period for which tenant operating results are available to us. Rent coverage is calculated using the annualized operating cash flows from our triple net lease tenants' operations of our properties, before subordinated charges, if any, divided by annualized rental income. We have not independently verified tenant operating data. Excludes data for historical periods prior to our ownership of certain properties.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

During the three months ended March 31, 2026, we entered into new and renewal leases in our Medical Office and Life Science Portfolio segment as summarized in the following table (dollars and square feet in thousands, except per square foot amounts):

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| | **New Leases** | **Renewals** | **Total** |
| Square feet leased during the quarter | 113 | 56 | 169 |
| Weighted average rental rate change (by rentable square feet) | 15.7% | 5.1% | 12.0% |
| Weighted average lease term (years) | 10.1 | 8.2 | 9.5 |
| Total leasing costs and concession commitments <sup>(1)</sup> | $3815 | $1228 | $5043 |
| Total leasing costs and concession commitments per square foot <sup>(1)</sup> | $33.80 | $21.78 | $29.79 |
| Total leasing costs and concession commitments per square foot per year <sup>(1)</sup> | $3.35 | $2.66 | $3.14 |

---

(1)Includes commitments made for leasing expenditures and concessions, such as tenant improvements, leasing commissions, tenant reimbursements and free rent.

As of March 31, 2026, lease expirations in our Medical Office and Life Science Portfolio segment were as follows (dollars in thousands):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|<br><br>**Year** |<br>**Number**<br>**of**<br>**Tenants** |<br>**Leased**<br>**Square Feet**<br>**Expiring** |<br>**% of Total**<br>**Leased**<br>**Square Feet**<br>**Expiring** | **Cumulative**<br>**% of Total**<br>**Leased**<br>**Square Feet**<br>**Expiring** |<br>**Annualized**<br>**Rental Income**<br>**Expiring** <sup>(1)</sup> |<br>**% of Total**<br>**Annualized**<br>**Rental Income**<br>**Expiring** | **Cumulative**<br>**% of Total**<br>**Annualized**<br>**Rental Income**<br>**Expiring** |
| 2026 | 34 | 485364 | 9.5% | 9.5% | $15611 | 9.5% | 9.5% |
| 2027 | 45 | 510390 | 10.0% | 19.5% | 13447 | 8.2% | 17.7% |
| 2028 | 42 | 1055047 | 20.7% | 40.2% | 31885 | 19.5% | 37.2% |
| 2029 | 44 | 472459 | 9.3% | 49.5% | 15249 | 9.3% | 46.5% |
| 2030 | 32 | 338925 | 6.6% | 56.1% | 8353 | 5.1% | 51.6% |
| Thereafter | 96 | 2237515 | 43.9% | 100.0% | 79346 | 48.4% | 100.0% |
| &nbsp;&nbsp;&nbsp;Total | 293 | 5099700 | 100.0% |  | $163891 | 100.0% |  |
| Weighted average remaining lease term (in years) | Weighted average remaining lease term (in years) | 4.6 |  |  | 4.9 |  |  |

---

(1)Annualized rental income is based on rents pursuant to existing leases as of March 31, 2026, and includes straight line rent adjustments and estimated recurring expense reimbursements for certain net and modified gross leases and excludes lease value amortization.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

As of March 31, 2026, lease expirations at our triple net leased wellness centers and senior living communities leased to third party operators were as follows (dollars in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|<br><br>**Year** |<br><br>**Number of**<br>**Properties** |<br>**Number of Units**<br>**Or**<br>**Square Feet** |<br>**Annualized**<br>**Rental Income**<br>**Expiring** <sup>(1)</sup> |<br>**% of Total**<br>**Annualized**<br>**Rental Income**<br>**Expiring** | **Cumulative**<br>**% of Total**<br>**Annualized**<br>**Rental Income**<br>**Expiring** |
| 2026 |  |  | $— | —% | —% |
| 2027 <sup>(2)</sup> | 4 | 533 units | 4841 | 16.0% | 16.0% |
| 2028 |  |  |  | —% | 16.0% |
| 2029 | 1 | 155 units | 547 | 1.8% | 17.8% |
| 2030 | 5 | 277 units and 129,600 square feet | 5062 | 16.7% | 34.5% |
| Thereafter | 9 | 363 units and 682,646 square feet | 19891 | 65.5% | 100.0% |
| &nbsp;&nbsp;&nbsp;Total | 19 |  | $30341 | 100.0% |  |
| Weighted average remaining lease term (in years) | Weighted average remaining lease term (in years) | Weighted average remaining lease term (in years) | 9.4 |  |  |

---

(1)Annualized rental income is based on rents pursuant to existing leases as of March 31, 2026. Annualized rental income includes estimated percentage rents and straight line rent adjustments and excludes lease value amortization.

(2)In April 2026, Stellar Senior Living LLC exercised its renewal option to extend its lease through 2037.

**<u>RESULTS OF OPERATIONS</u> *(dollars in thousands, unless otherwise noted)***

We operate in, and report financial information for, the following two segments: SHOP and Medical Office and Life Science Portfolio. Our SHOP segment consists of managed senior living communities that provide short term and long term residential living and, in some instances, care and other services for residents where we pay fees to managers to operate the communities on our behalf. Our Medical Office and Life Science Portfolio segment primarily consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties primarily leased to biotech laboratories and other similar tenants.

We also report "All Other" operations, which consists of triple net leased wellness centers and senior living communities that are leased to third party operators from which we receive rents, which we do not consider to be sufficiently material to constitute a separate reportable segment, and any other income or expenses that are not attributable to a specific reportable segment.

The following table summarizes the results of operations of each of our segments for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenues: |  |  |
| SHOP | $317225 | $328306 |
| Medical Office and Life Science Portfolio | 41895 | 49763 |
| All Other | 7351 | 8795 |
| &nbsp;&nbsp;Total revenues | $366471 | $386864 |
| Net loss: |  |  |
| SHOP | $(11056) | $(3087) |
| Medical Office and Life Science Portfolio | 9464 | (18736) |
| All Other | (41683) | 12837 |
| &nbsp;&nbsp;Net loss | $(43275) | $(8986) |

---

The following section analyzes and discusses the results of operations of each of our segments for the periods presented.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

***Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025 (dollars in thousands):***

Unless otherwise indicated, references in this section to changes or comparisons of results, income or expenses refer to comparisons of the results for the three months ended March 31, 2026 to the three months ended March 31, 2025. Our definition of NOI and our reconciliation of net income (loss) to NOI and a description of why we believe NOI is an appropriate supplemental measure are included below under the heading "Non-GAAP Financial Measures."

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** | **$ Change** | **% Change** |
| NOI by segment: |  |  |  |  |
| SHOP | $43626 | $36828 | $6798 | 18.5% |
| Medical Office and Life Science Portfolio | 25064 | 26856 | (1792) | (6.7)% |
| All Other | 7225 | 8854 | (1629) | (18.4)% |
| &nbsp;&nbsp;Total NOI | 75915 | 72538 | 3377 | 4.7% |
| Depreciation and amortization | 62914 | 68325 | (5411) | (7.9)% |
| General and administrative | 14038 | 9000 | 5038 | 56.0% |
| Acquisition and certain other transaction related costs | 3693 | 24 | 3669 | n/m |
| Impairment of assets |  | 38472 | (38472) | (100.0)% |
| (Loss) gain on sale of real estate | (1207) | 110140 | (111347) | (101.1)% |
| Gain on insurance recoveries |  | 7522 | (7522) | (100.0)% |
| Interest and other income | 233 | 2099 | (1866) | (88.9)% |
| Interest expense | (37045) | (57831) | 20786 | (35.9)% |
| Loss on modification or early extinguishment of debt |  | (29071) | 29071 | (100.0)% |
| Loss before income taxes and equity in net earnings of investees | (42749) | (10424) | (32325) | n/m |
| Income tax expense | (622) | (49) | (573) | n/m |
| Equity in net earnings of investees | 96 | 1487 | (1391) | (93.5)% |
| Net loss | $(43275) | $(8986) | $(34289) | n/m |

---

n/m - not meaningful

***SHOP:***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Comparable** <sup>(1)</sup> | **Comparable** <sup>(1)</sup> | **Comparable** <sup>(1)</sup> | **Non-Comparable** | **Non-Comparable** | **Consolidated** | **Consolidated** | **Consolidated** |
| | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** |
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** |
| | **2026** | **2025** | $**%**<br>**Change** | **2026** | **2025** | **2026** | **2025** | $**%**<br>**Change** |
| Residents fees and services | $296504 | $283106 | 4.7% | $20721 | $45200 | $317225 | $328306 | (3.4)% |
| Property operating expenses | (252183) | (244069) | 3.3% | (21416) | (47409) | (273599) | (291478) | (6.1)% |
| NOI | $44321 | $39037 | 13.5% | $(695) | $(2209) | $43626 | $36828 | 18.5% |

---

(1)Consists of senior living communities that we have owned, are in service and reported in the same segment since January 1, 2025; excludes communities classified as held for sale, planned for sale, closed or out of service, if any. Properties are included in same property once stabilized for the full period in both comparison periods presented.

*Residents fees and services.* Residents fees and services are the revenues earned at our managed senior living communities. We recognize these revenues as services are provided and related fees are accrued. Residents fees and services increased at our comparable properties primarily due to increases in occupancy and average monthly rate at our communities. Residents fees and services decreased at our non-comparable properties primarily due to dispositions since January 1, 2025.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

*Property operating expenses.* Property operating expenses consist of real estate taxes, utility expenses, insurance, wages and benefit costs of community level personnel, repairs and maintenance expense, management fees, cleaning expense and other direct costs of operating these communities. Property operating expenses increased at our comparable properties primarily due to increases in labor costs, management fees as a result of higher revenues, insurance costs and other direct costs, partially offset by decreases in maintenance and repair costs. Property operating expenses decreased at our non-comparable properties primarily due to dispositions since January 1, 2025.

*Net operating income.* The change in NOI reflects the net changes in residents fees and services and property operating expenses described above.

***Medical Office and Life Science Portfolio:***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Comparable** <sup>(1)</sup> | **Comparable** <sup>(1)</sup> | **Comparable** <sup>(1)</sup> | **Non-Comparable** | **Non-Comparable** | **Consolidated** | **Consolidated** | **Consolidated** |
| | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** |
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** |
| | **2026** | **2025** | $**%**<br>**Change** | **2026** | **2025** | **2026** | **2025** | $**%**<br>**Change** |
| Rental income | $41849 | $40630 | 3.0% | $46 | $9133 | $41895 | $49763 | (15.8)% |
| Property operating expenses | (16481) | (16174) | 1.9% | (350) | (6733) | (16831) | (22907) | (26.5)% |
| NOI | $25368 | $24456 | 3.7% | $(304) | $2400 | $25064 | $26856 | (6.7)% |

---

(1)Consists of medical office and life science properties that we have owned and which have been in service continuously since January 1, 2025; excludes properties classified as held for sale, planned for sale or out of service undergoing redevelopment, if any, and properties owned by unconsolidated joint ventures in which we own an equity interest. Properties are included in same property once stabilized for the full period in both comparison periods presented.

*Rental income.* Rental income increased at our comparable properties primarily due to increases from our net leasing activity and property operating expense reimbursements at certain of our properties. Rental income decreased at our non-comparable properties primarily due to dispositions since January 1, 2025.

*Property operating expenses.* Property operating expenses consist of real estate taxes, utility expenses, insurance, management fees, salaries and benefit costs of property level personnel, repairs and maintenance expense, cleaning expense and other direct costs of operating these properties. The increase in property operating expenses at our comparable properties is primarily due to an increase in real estate taxes and other direct costs. Property operating expenses decreased at our non-comparable properties primarily due to dispositions since January 1, 2025.

*Net operating income.* The change in NOI reflects the net changes in rental income and property operating expenses described above.

***All Other:***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Comparable** <sup>(1)</sup> | **Comparable** <sup>(1)</sup> | **Comparable** <sup>(1)</sup> | **Non-Comparable** | **Non-Comparable** | **Consolidated** | **Consolidated** | **Consolidated** |
| | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** | **Properties Results** |
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** | **March 31,** |
| | **2026** | **2025** | $**%**<br>**Change** | **2026** | **2025** | **2026** | **2025** | $**%**<br>**Change** |
| Rental income | $7165 | $7120 | 0.6% | $186 | $1675 | $7351 | $8795 | (16.4)% |
| Property operating expenses <sup>(2)</sup> | (126) | 59 | n/m |  |  | (126) | 59 | n/m |
| NOI | $7039 | $7179 | (2.0)% | $186 | $1675 | $7225 | $8854 | (18.4)% |

---

n/m - not meaningful

(1)Consists of properties that we have owned and which have been reported in the same segment and leased to the same operator continuously since January 1, 2025; excludes properties classified as held for sale and planned dispositions, if any. Properties are included in same property once stabilized for the full period in both comparison periods presented.

(2)For the three months March 31, 2025, we recognized a net credit of $59 related to tax refunds received during the period.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

*Rental income.* There have been no material changes in rental income at our comparable properties. The activity for our non-comparable properties primarily reflects the 18 triple net leased senior living communities that we sold in February 2025 as well as one senior living community that transitioned to a triple net lease in December 2025.

*Property operating expenses.* Property operating expenses consist of real estate taxes, insurance and other expenses that are not paid directly by our tenants. There have been no material changes in property operating expenses.

*Net operating income.* The change in NOI primarily reflects the change in rental income described above.

***Consolidated:***

*Depreciation and amortization expense.* Depreciation and amortization expense decreased primarily due to dispositions since January 1, 2025 and certain depreciable assets becoming fully depreciated, partially offset by the purchase of capital improvements at certain of our properties.

*General and administrative expense*. General and administrative expense consists of fees paid to RMR under our business management agreement, legal and accounting fees, fees and expenses of our Trustees, equity compensation expense and other costs relating to our status as a publicly traded company. General and administrative expense increased primarily due to $6,628 of estimated incentive management fees that we recognized for the three months ended March 31, 2026, compared to $2,407 for the three months ended March 31, 2025. These incentive management fees were recorded as a result of our total shareholder return exceeding the returns for the MSCI U.S. REIT/Health Care REIT Index over the applicable measurement period.

*Acquisition and certain other transaction related costs.* Acquisition and certain other transaction related costs primarily represent costs incurred with acquisitions and non-recurring transactions that we expensed under GAAP. During the three months ended March 31, 2026, we incurred transition costs as a result of our transition of 116 communities to both new and existing third party managers.

*Impairment of assets.* For information about our asset impairment charges, see Note 3 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q and Note 3 to our consolidated financial statements included in Part IV, Item 15 of our Annual Report.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(Loss) gain on sale of real estate.* For information regarding (loss) gain on sale of real estate, see Note 3 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q and Note 3 to our consolidated financial statements included in Part IV, Item 15 of our Annual Report.

*Gain on insurance recoveries.* During the three months ended March 31, 2025, we recognized a gain on insurance recoveries related to cash received from our insurance provider in excess of our losses for a claim that was finalized. For further information regarding this gain on insurance recoveries, see Note 3 to our consolidated financial statements included in Part IV, Item 15 of our Annual Report.

*Interest and other income.* The decrease in interest and other income is primarily due to lower average invested cash balances and interest rates during the three months ended March 31, 2026.

*Interest expense.* Interest expense decreased primarily due to a decrease in discount accretion for our then senior secured notes due 2026 due to the full redemption of the remaining balance of these notes during 2025. During the three months ended March 31, 2025, we recognized discount accretion of $22,122 for our then outstanding senior secured notes due 2026. Interest expense also decreased due to the redemption during 2025 of an aggregate $380,000 of our then remaining 9.75% senior unsecured notes due 2025. These decreases were partially offset by the issuance of $375,000 in aggregate principal amount of our 7.25% senior secured notes due 2030 in September 2025 and four mortgage financings totaling $343,157 during 2025.

*Loss on modification or early extinguishment of debt.* During the three months ended March 31, 2025, we recorded a loss on early extinguishment of debt in connection with the partial redemption of an aggregate $299,158 of our outstanding senior secured notes due 2026.

*Income tax expense*. Income tax expense is the result of operating income we earned in certain jurisdictions where we are subject to state income taxes.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

*Equity in net earnings of investees.* Equity in net earnings of investees is the change in the fair value of our investments in our unconsolidated joint ventures and also represented our proportionate share of the earnings of our equity method investment in AlerisLife. As of December 31, 2025, AlerisLife had ceased operations and was in the process of winding down its business. We recognized no equity in net earnings of AlerisLife for the three months ended March 31, 2026. For further information regarding our investment in AlerisLife, see Notes 3 and 11 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

**Non-GAAP Financial Measures *(dollars in thousands, except per share amounts)***

We present certain "non-GAAP financial measures" within the meaning of the applicable rules of the Securities and Exchange Commission, or the SEC, including funds from operations, or FFO, normalized funds from operations, or Normalized FFO, and NOI for the three months ended March 31, 2026 and 2025. These measures do not represent cash generated by operating activities in accordance with GAAP and should not be considered alternatives to net income (loss) as indicators of our operating performance or as measures of our liquidity. These measures should be considered in conjunction with net income (loss) as presented in our condensed consolidated statements of comprehensive income (loss). We consider these non-GAAP measures to be appropriate supplemental measures of operating performance for a REIT, along with net income (loss). We believe these measures provide useful information to investors because by excluding the effects of certain historical amounts, such as depreciation and amortization, they may facilitate a comparison of our operating performance between periods and with other REITs and, in the case of NOI, reflecting only those income and expense items that are generated and incurred at the property level may help both investors and management to understand the operations of our properties.

*Funds From Operations and Normalized Funds From Operations*

We calculate FFO and Normalized FFO as shown below. FFO is calculated on the basis defined by the National Association of Real Estate Investment Trusts, which is net income (loss), calculated in accordance with GAAP, excluding any gain or loss on sale of real estate, equity in net earnings or losses of investees, loss on impairment of real estate assets, gains or losses on equity securities, net, if any, and including adjustments to reflect our proportionate share of FFO of our unconsolidated joint venture properties and prior to the wind-down of AlerisLife's business, our proportionate share of FFO of our former equity method investment, plus real estate depreciation and amortization of consolidated properties, as well as certain other adjustments currently not applicable to us. In calculating Normalized FFO, we adjust for the items shown below including similar adjustments for our unconsolidated joint ventures and incentive management fees, if any. FFO and Normalized FFO are among the factors considered by our Board of Trustees when determining the amount of distributions to our shareholders. Other factors include, but are not limited to, requirements to maintain our qualification for taxation as a REIT, limitations in the agreements governing our debt, the availability to us of debt and equity capital, our expectation of our future capital requirements and operating performance and our expected needs for and availability of cash to pay our obligations. Other real estate companies and REITs may calculate FFO and Normalized FFO differently than we do.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

Our calculations of FFO and Normalized FFO for the three months ended March 31, 2026 and 2025 and reconciliations of net income (loss), the most directly comparable financial measure under GAAP reported in our condensed consolidated financial statements, to FFO and Normalized FFO appear in the following table. This table also provides a comparison of distributions to shareholders, FFO and Normalized FFO and net income (loss) per share for these periods.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net loss | $(43275) | $(8986) |
| &nbsp;&nbsp;Depreciation and amortization | 62914 | 68325 |
| &nbsp;&nbsp;Loss (gain) on sale of real estate | 1207 | (110140) |
| &nbsp;&nbsp;Impairment of assets |  | 38472 |
| &nbsp;&nbsp;Equity in net earnings of investees | (96) | (1487) |
| &nbsp;&nbsp;Share of FFO from unconsolidated joint ventures | 2027 | 2737 |
| &nbsp;&nbsp;Adjustments to reflect our share of FFO attributable to a former equity method investment |  | 1073 |
| FFO | 22777 | (10006) |
| &nbsp;&nbsp;Incentive management fees <sup>(1)</sup> | 6628 | 2407 |
| &nbsp;&nbsp;Acquisition and certain other transaction related costs <sup>(2)</sup> | 3693 | 24 |
| &nbsp;&nbsp;Gain on insurance recoveries |  | (7522) |
| &nbsp;&nbsp;Loss on modification or early extinguishment of debt |  | 29071 |
| &nbsp;&nbsp;Adjustments to reflect our share of Normalized FFO attributable to a former equity method investment |  | 331 |
| Normalized FFO | $33098 | $14305 |
| Weighted average common shares outstanding (basic and diluted) | 240689 | 239957 |
| Per common share data (basic and diluted): |  |  |
| Net loss | $(0.18) | $(0.04) |
| FFO | $0.09 | $(0.04) |
| Normalized FFO | $0.14 | $0.06 |
| Distributions declared | $0.01 | $0.01 |

---

(1)Incentive management fees are estimated and accrued during the applicable measurement period. Actual incentive management fees are calculated based on common share total return, as defined in our business management agreement, for the three year period ending December 31 of the applicable calendar year, and are included in general and administrative expenses in our condensed consolidated statements of comprehensive income (loss) and are payable to RMR in January of the following calendar year. In calculating net income (loss) in accordance with GAAP, we recognize estimated incentive management fees expense, if any, in the first, second and third quarters. Although we recognize this expense, if any, in the first, second and third quarters for purposes of calculating net income (loss), we do not include these amounts in the calculation of Normalized FFO until the fourth quarter, when the amount of the incentive management fees expense for the calendar year, if any, is determined.

(2)Acquisition and certain other transaction related costs primarily represent costs incurred with acquisitions and non-recurring transactions that we expensed under GAAP. During the three months ended March 31, 2026, we incurred transition costs as a result of our transition of 116 communities to both new and existing third party managers.

*Property Net Operating Income (NOI)*

We calculate NOI as shown below. The calculation of NOI excludes certain components of net income (loss) in order to provide results that are more closely related to our property level results of operations. We define NOI as income from our real estate less our property operating expenses. NOI excludes depreciation and amortization. We use NOI to evaluate individual and company-wide property level performance. Other real estate companies and REITs may calculate NOI differently than we do.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

The calculation of NOI by reportable segment is included above in this Item 2. The following table includes the reconciliation of net income (loss) to NOI for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net loss | $(43275) | $(8986) |
| Equity in net earnings of investees | (96) | (1487) |
| Income tax expense | 622 | 49 |
| Loss before income taxes and equity in net earnings of investees | (42749) | (10424) |
| Loss on modification or early extinguishment of debt |  | 29071 |
| Interest expense | 37045 | 57831 |
| Interest and other income | (233) | (2099) |
| Gain on insurance recoveries |  | (7522) |
| Loss (gain) on sale of real estate | 1207 | (110140) |
| Impairment of assets |  | 38472 |
| Acquisition and certain other transaction related costs | 3693 | 24 |
| General and administrative | 14038 | 9000 |
| Depreciation and amortization | 62914 | 68325 |
| &nbsp;&nbsp;&nbsp;NOI | $75915 | $72538 |
| **NOI by segment:** |  |  |
| SHOP | $43626 | $36828 |
| Medical Office and Life Science Portfolio | 25064 | 26856 |
| All Other | 7225 | 8854 |
| &nbsp;&nbsp;&nbsp;Total | $75915 | $72538 |

---

**<u>LIQUIDITY AND CAPITAL RESOURCES</u> *(dollars in thousands)***

Our principal sources of cash to meet operating and capital expenses, pay our debt service obligations and make distributions to our shareholders are the operating cash flows we generate as residents fees and services revenues from our managed communities, rental income from our leased properties and proceeds from the disposition of certain properties. We believe that these sources of funds will be sufficient to meet our operating and capital expenses, pay our debt service obligations and make distributions to our shareholders for at least the next 12 months and for the foreseeable future thereafter. Our future cash flows from operating activities will depend primarily upon:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain or increase the occupancy of, and the rates at, our properties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to receive rents from our tenants;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our and our managers' abilities to control operating expenses and capital expenses at our properties, including increased operating expenses that we may incur in response to wage and commodity price inflation, limited labor availability and increased insurance costs; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our managers' abilities to maintain or increase our returns from our managed senior living communities.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

The following is a summary of our sources and uses of cash flows for the periods presented, as reflected in our condensed consolidated statements of cash flows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Cash and cash equivalents and restricted cash at beginning of period | $121799 | $149854 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating activities | 8342 | (3243) |
| &nbsp;&nbsp;&nbsp;&nbsp;Investing activities | 13580 | 291093 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing activities | (3869) | (131049) |
| Cash and cash equivalents and restricted cash at end of period | $139852 | $306655 |

---

***Our Operating Liquidity and Resources***

We receive residents fees and services revenues, net of expenses, from our managed senior living communities monthly, we generally receive minimum rents from tenants at our senior living communities, medical office and life science properties and triple net leased wellness centers monthly and we receive percentage rents from tenants at certain of our triple net leased senior living communities monthly, quarterly or annually.

The change in cash provided by (used in) operating activities for the three months ended March 31, 2026 compared to the prior period was primarily due to a reduction in interest paid during the 2026 period primarily due to accreted interest of $34,700 paid during the 2025 period as a result of the partial redemption of our then outstanding senior secured notes due 2026. This increase was partially offset by the payment of a $17,905 incentive management fee pursuant to our business management agreement for the year ended December 31, 2025. We paid this incentive management fee to RMR in January 2026.

***Our Investing Liquidity and Resources***

The decrease in cash provided by investing activities for the three months ended March 31, 2026 compared to the prior period was primarily due to a decrease in proceeds from the sale of real estate, partially offset by an increase in cash dividends paid to us by AlerisLife and our $5,800 of contributions made to the Seaport JV in the 2025 period.

In connection with the wind-down of its business, on January 9, 2026, AlerisLife paid an aggregate cash dividend of $80,000 to its stockholders, and our pro rata share of this cash dividend was $27,200.

*Capital Expenditures*

As of March 31, 2026, we had estimated unspent leasing related obligations at our medical office and life science properties of approximately $11,123, of which we expect to spend approximately $8,811 during the next 12 months. We expect to fund these obligations using operating cash flows and cash on hand.

We generally plan to continue investing capital in our properties, including redevelopment projects, to better position these properties in their respective markets in order to increase our returns in future years. We are currently in the process of redeveloping certain properties, primarily our managed senior living communities. We continue to assess opportunities to redevelop other properties in our SHOP segment and Medical Office and Life Science Portfolio segment. These redevelopment projects may require significant capital expenditures and time to complete and we may defer certain redevelopment projects to preserve liquidity. Additionally, due to labor availability constraints and wage and commodity price inflation, the capital investments we plan to make may be delayed or cost more than we expect.

For further information regarding our capital expenditures, see Note 3 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

*Dispositions*

During the three months ended March 31, 2026, we sold 13 properties for an aggregate sales price of $23,000, excluding closing costs.

For further information regarding our dispositions, see Note 3 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

*Acquisitions*

In April 2026, we acquired two land parcels located in Lexington, Kentucky previously subject to finance leases pursuant to our exercise of a purchase option for an aggregate purchase price of $14,500, excluding closing costs.

***Our Financing Liquidity and Resources***

The decrease in cash used in financing activities for the three months ended March 31, 2026 compared to the prior period was primarily due to the partial redemption of our then outstanding senior secured notes due 2026, partially offset by our incurrence of a $140,000 mortgage loan, in the 2025 period.

As of March 31, 2026, we had $121,774 of cash and cash equivalents. We typically use cash balances, net proceeds from offerings of securities, debt issuances or dispositions of assets and cash flows from our operations to fund our operations, debt repayments, distributions, acquisitions, investments, capital expenditures and other general business purposes.

Our revolving credit facility is available for general business purposes, including acquisitions. We can borrow, repay and reborrow funds available under our revolving credit facility, and no principal repayments are due, until maturity. Availability of borrowings under our credit agreement is subject to satisfying certain financial covenants and other credit facility conditions. Our revolving credit facility matures in June 2029 and we have two six-month extension options for the maturity date of the facility, subject to satisfaction of certain conditions and payment of an extension fee.

Interest payable on borrowings under our revolving credit facility is based on daily SOFR plus a premium of 2.50% to 3.00%, depending on our net leverage ratio, as defined in our credit agreement, which was 2.50% as of March 31, 2026. We also pay an unused commitment fee of 25 to 35 basis points per annum based on amounts outstanding under our revolving credit facility. As of March 31, 2026, the annual interest rate payable on borrowings under our revolving credit facility was 6.28%. As of March 31, 2026 and April 30, 2026, we had no borrowings under our revolving credit facility and $150,000 available for borrowings.

*Distributions*

During the three months ended March 31, 2026, we paid a quarterly cash distribution to our shareholders totaling approximately $2,421 using cash on hand. On April 9, 2026, we declared a quarterly distribution to common shareholders of record on April 21, 2026 of $0.01 per share, or approximately $2,421. We expect to pay this distribution on or about May 14, 2026 using cash on hand.

*Indebtedness*

Our principal debt obligations at March 31, 2026 were: (1) $1,600,000 outstanding principal amount of senior unsecured notes; (2) $375,000 outstanding principal amount of senior secured notes secured by 36 properties; (3) $327,774 aggregate principal amount of fixed rate mortgage notes secured by 22 properties; and (4) $140,000 principal amount floating rate mortgage loan secured by 14 properties. For further information regarding our indebtedness, see Note 6 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

In April 2026, Moody's Investors Service, or Moody's, upgraded our issuer credit rating from Caa1 to B3, our senior secured notes due 2030 rating from B3 to B2, our 4.375% senior notes due 2031 rating from Caa1 to B3, and our senior unsecured notes from Caa2 to Caa1. Moody's also updated our ratings outlook to positive.

For further information regarding our outstanding debt, see Note 6 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

Our senior notes are governed by our senior notes indentures and their supplements. Our credit agreement, our mortgage loan agreements and our senior notes indentures and their supplements provide for acceleration of payment of all amounts outstanding upon the occurrence and continuation of certain events of default. Our credit agreement and our senior notes indentures and their supplements also contain covenants that restrict our ability to incur debts, including debts secured by mortgages on our properties, in excess of calculated amounts and require us to maintain various financial ratios. As of March 31, 2026, we believe we were in compliance with all of the covenants under our debt agreements. Although we continue to take steps to enhance our ability to maintain sufficient liquidity, as noted elsewhere in this Quarterly Report on Form 10-Q, a protracted negative impact on the economy or the industries in which our properties and businesses operate resulting from wage or commodity price inflation, high interest rates, geopolitical risks or other economic, market or industry conditions, including the delayed recovery of the senior housing industry, economic downturns or a possible recession, may cause increased pressure on our ability to satisfy financial and other covenants. If our operating results and financial condition are significantly negatively impacted by economic conditions or otherwise, we may fail to satisfy our debt covenants and conditions.

Our senior notes indentures and their supplements do not contain provisions for acceleration which could be triggered by our debt ratings. See "—Our Financing Liquidity and Resources" above for information regarding recent changes to our issuer credit rating and senior debt ratings.

Our revolving credit facility contains cross default provisions to any other debts of more than $25,000. Our senior unsecured notes indentures and their supplements contain cross default provisions to any other debts of more than $20,000 ($50,000 or more in the case of our senior notes indentures and supplements entered in February 2016, February 2018, February 2021 and September 2025).

The loan agreements governing the aggregate $1,000,000 secured debt financing related to the Seaport JV contain customary covenants and provide for acceleration of payment of all amounts due thereunder upon the occurrence and continuation of certain events of default. We provide certain limited recourse guaranties on this debt, with our liability limited to $100,000. The debt secured by the properties included in the LSMD JV in which we own a 20% equity interest is guaranteed by this joint venture and is non-recourse to us.

*Supplemental Guarantor Information*

On February 3, 2021, we issued $500,000 of our 4.375% senior notes due 2031. As of March 31, 2026, all $500,000 of our 4.375% senior notes due 2031 were fully and unconditionally guaranteed, on a joint, several and unsecured basis, by all of our subsidiaries except certain excluded subsidiaries. The notes and related guarantees are effectively subordinated to all of our and the subsidiary guarantors' secured indebtedness, respectively, to the extent of the value of the applicable collateral, and are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes. Our remaining $1,100,000 of senior unsecured notes do not have the benefit of any guarantees.

A subsidiary guarantor's guarantee of our 4.375% senior notes due 2031 and all other obligations of such subsidiary guarantor under the indenture governing the notes will automatically terminate and such subsidiary guarantor will automatically be released from all of its obligations under such subsidiary guarantee and the indenture under certain circumstances, including on or after the date (a) the notes have an investment grade rating from two rating agencies and one of such investment grade ratings is a mid-BBB investment grade rating and (b) no default or event of default has occurred and is continuing under the indenture. Our non-guarantor subsidiaries are separate and distinct legal entities and have no obligation, contingent or otherwise, to pay any amounts due on our 4.375% senior notes due 2031 or their guarantees, or to make any funds available therefor, whether by dividend, distribution, loan or other payments. The rights of holders of our 4.375% senior notes due 2031 to benefit from any of the assets of our non-guarantor subsidiaries are subject to the prior satisfaction of claims of those subsidiaries' creditors and any preferred equity holders. As a result, our 4.375% senior notes due 2031 and their guarantees are structurally subordinated to all indebtedness, guarantees and other liabilities of our subsidiaries that do not guarantee our 4.375% senior notes due 2031, including guarantees of other indebtedness of ours, payment obligations under lease agreements, trade payables and preferred equity.

The following tables present summarized financial information for guarantor entities and issuer, on a combined basis after eliminating (i) intercompany transactions and balances among the guarantor entities and (ii) equity in earnings from, and any investments in, any subsidiary that is a non-guarantor:

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31, 2026** | **December 31, 2025** |
| Real estate properties, net | $2427843 | $2452118 |
| Other assets, net | 305033 | 333731 |
| Total assets | $2732876 | $2785849 |
| Indebtedness, net | $1946942 | $1945732 |
| Other liabilities | 153986 | 192526 |
| Total liabilities | $2100928 | $2138258 |

---

---

| | |
|:---|:---|
| | **Three Months Ended**<br>**March 31, 2026** |
| Revenues | $219921 |
| Expenses | $242625 |
| Loss from continuing operations | $(50732) |
| Net loss | $(51285) |

---

***Related Person Transactions***

We have relationships and historical and continuing transactions with RMR, RMR Inc., AlerisLife (including Five Star) and others related to them. For further information about these and other such relationships and related person transactions, see Notes 4, 10 and 11 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, our Annual Report, our definitive Proxy Statement for our 2026 Annual Meeting of Shareholders and our other filings with the SEC. In addition, see the section captioned "Risk Factors" of our Annual Report for a description of risks that may arise as a result of these and other related person transactions and relationships. We may engage in additional transactions with related persons, including businesses to which RMR or its subsidiaries provide management services.

***Critical Accounting Estimates***

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect reported amounts. Actual results could differ from those estimates. Significant estimates in our condensed consolidated financial statements include purchase price allocations, useful lives of fixed assets and impairments of real estate and intangible assets.

A discussion of our critical accounting estimates is included in our Annual Report. There have been no significant changes in our critical accounting estimates since the year ended December 31, 2025.

***Impact of Government Reimbursement***

For the three months ended March 31, 2026, substantially all of our NOI was generated from properties where a majority of the revenues are derived from our tenants' and residents' private resources, and a small amount of our NOI was generated from properties where a majority of the revenues are derived from Medicare and Medicaid payments. Nonetheless, we own, and our tenants, managers and operators operate, facilities in many states that participate in federal and state healthcare payment programs, including the federal Medicare and state Medicaid programs and other federal and state healthcare payment programs. Also, some of our medical office and life science property tenants participate in federal Medicare and state Medicaid programs and other government healthcare payment programs.

For more information regarding the government healthcare funding and regulation of our business, please see the section captioned "Business—Government Regulation and Reimbursement" in our Annual Report and the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations—Impact of Government Reimbursement" in our Annual Report.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.** 

***(dollars in thousands, except per share data)***

We are exposed to risks associated with market changes in interest rates. We manage our exposure to this market risk by monitoring available financing alternatives, including fixed rate debt, and employing derivative instruments, including interest rate caps, to limit our exposure to increasing interest rates. Other than as described below, we do not currently expect any significant changes in our exposure to fluctuations in interest rates or in how we manage this exposure in the near future.

*Floating Rate Debt*

As of March 31, 2026, our outstanding floating rate debt consisted of the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|<br>**Debt** | **Principal**<br>**Balance** | **Annual Interest**<br>**Rate** <sup>(1)</sup> | **Annual Interest**<br>**Expense** | **Maturity**<br>**Date** | **Interest**<br>**Payments Due** |
| Floating rate mortgage loan | $140000 | 6.17% | $8758 | 3/31/2028 | Monthly |
| Floating rate secured revolving credit facility |  |  |  | 6/11/2029 | Monthly |
| &nbsp;&nbsp;&nbsp;Total | $140000 |  | $8758 |  |  |

---

(1)The annual interest rate is the rate stated in the applicable contract, as adjusted by our interest rate cap, if applicable.

Our $140,000 floating rate mortgage loan is subject to two one-year extension options and requires that interest be paid at one-month term SOFR plus a premium of 2.50%. We are vulnerable to changes in the U.S. dollar based on short term interest rates, specifically SOFR. In connection with this mortgage loan, to hedge our exposure to risks related to changes in SOFR and pursuant to the terms of the applicable loan agreement, we have purchased an interest rate cap with a one-month term SOFR strike rate equal to 4.50%.

At March 31, 2026, we had no amounts outstanding under our revolving credit facility. No principal repayments are required under our revolving credit facility prior to maturity and repayments may be made and redrawn subject to conditions at any time without penalty.

Borrowings under our revolving credit facility are in U.S. dollars and require interest to be paid at a rate of daily SOFR plus a premium. Accordingly, we are vulnerable to changes in the U.S. dollar based short term interest rates, specifically SOFR. In addition, upon renewal or refinancing of these obligations, we are vulnerable to increases in interest rate premiums, including increases in the cost of replacement interest rate caps, due to market conditions and our perceived credit risk. The following table presents the approximate impact a one percentage point increase in interest rates would have on our annual floating rate interest expense at March 31, 2026, including the impact of our interest rate cap:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Impact of an Increase in Interest Rates** | **Impact of an Increase in Interest Rates** | **Impact of an Increase in Interest Rates** | **Impact of an Increase in Interest Rates** |
| |<br>**Interest Rate** <sup>(1)</sup> |<br>**Outstanding Debt** | **Total Interest**<br>**Expense Per Year** | **Annual Earnings**<br>**Per Share Impact** <sup>(2)</sup> |
| As of March 31, 2026 | 6.17% | $140000 | $8758 | $(0.04) |
| &nbsp;&nbsp;&nbsp;One percentage point increase <sup>(3)</sup> | 7.00% | $140000 | $9936 | $(0.04) |

---

(1)Based on one-month term SOFR plus a premium, which was 250 basis points per annum for our $140,000 floating rate mortgage loan, as of March 31, 2026.

(2)Based on the diluted weighted average common shares outstanding for the three months ended March 31, 2026.

(3)A one percentage point increase in interest rates would be capped at 7.00% for our $140,000 floating rate mortgage loan as a result of our 4.50% interest rate cap purchased for this debt. However, a one percentage point increase in the interest rate of our floating rate debt to 7.17% at March 31, 2026 would result in total floating rate interest expense per year of 10,177 and a decrease in annual earnings per share of $0.04.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

The following table presents the impact a one percentage point increase in interest rates would have on our annual floating rate interest expense at March 31, 2026 if we were fully drawn on our revolving credit facility:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Impact of an Increase in Interest Rates** | **Impact of an Increase in Interest Rates** | **Impact of an Increase in Interest Rates** | **Impact of an Increase in Interest Rates** |
| |<br>**Interest Rate** <sup>(1)</sup> |<br>**Outstanding Debt** <sup>(2)</sup> | **Total Interest**<br>**Expense Per Year** | **Annual Earnings**<br>**Per Share Impact** <sup>(3)</sup> |
| As of March 31, 2026 | 6.23% | $290000 | $18318 | $(0.08) |
| &nbsp;&nbsp;&nbsp;One percentage point increase <sup>(4)</sup> | 7.14% | $290000 | $20994 | $(0.09) |

---

(1)Based on the applicable SOFR plus a premium, which was 260 basis points per annum for our revolving credit facility and 250 basis points per annum for our $140,000 floating rate mortgage loan as of March 31, 2026. Interest rate is weighted based on amounts outstanding.

(2)Represents the maximum amount available under our revolving credit facility and our $140,000 floating rate mortgage loan.

(3)Based on the diluted weighted average common shares outstanding for the three months ended March 31, 2026.

(4)A one percentage point increase in interest rates would be capped at 7.00% for our $140,000 floating rate mortgage loan as a result of our 4.50% interest rate cap purchased for this debt. However, a one percentage point increase in the interest rate of our floating rate debt to 7.23% at March 31, 2026 would result in total floating rate interest expense per year of $21,258 and a decrease in annual earnings per share of $0.09.

The foregoing tables show the impact of an immediate one percentage point change in floating interest rates, including the impact of our interest rate cap. Our exposure to fluctuations in floating interest rates will increase or decrease in the future with increases or decreases in the outstanding amounts of any floating rate debt we may incur and the impact, if any, of interest rate caps we may purchase. Generally, if interest rates were to change gradually over time, the impact would be spread over time.

*Fixed Rate Debt*

There have been no material changes to market interest rate risks associated with our fixed rate debt from those we previously disclosed in our Annual Report. For a discussion of market interest rate risks associated with our fixed rate debt, see "Quantitative and Qualitative Disclosures About Market Risk" included in Part II, Item 7A of our Annual Report.

**Item 4. Controls and Procedures.**

As of the end of the period covered by this Quarterly Report on Form 10-Q, our management carried out an evaluation, under the supervision and with the participation of our President and Chief Executive Officer and our Chief Financial Officer and Treasurer, of the effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934, as amended. Based upon that evaluation, our President and Chief Executive Officer and our Chief Financial Officer and Treasurer concluded that our disclosure controls and procedures are effective.

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**<u>Warning Concerning Forward-Looking Statements</u>**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws that are subject to risks and uncertainties. These statements may include words such as "believe", "expect", "anticipate", "intend", "plan", "estimate", "will", "may" and negatives or derivatives of these or similar expressions. These forward-looking statements include, among others, statements about: our efforts to manage costs and our expectations regarding occupancy and average monthly rates at our SHOP communities; market demand and supply for healthcare services for older adults and senior living communities; demand for medical office and life science leased space; our future leasing activity; our leverage; the sufficiency of our liquidity; our liquidity needs and sources; our capital expenditure plans and commitments; our property acquisitions and dispositions; our redevelopment, repositioning and construction activities and plans; and the amount and timing of future distributions.

Forward-looking statements reflect our current expectations, are based on judgments and assumptions, are inherently uncertain and are subject to risks, uncertainties and other factors, which could cause our actual results, performance or achievements to differ materially from expected future results, performance or achievements expressed or implied in those forward-looking statements. Some of the risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include, but are not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The impact of unfavorable market and commercial real estate industry conditions due to possible reduced demand for healthcare related space and senior living communities, uncertainties surrounding interest rates, wage and commodity price inflation, supply chain disruptions, volatility in the public debt and equity markets, changing tariffs and trade policies and related uncertainty, geopolitical instability and tensions, pandemics, any U.S. government shutdown, economic downturns or a possible recession, labor market conditions or changes in real estate utilization, among other things, on us and our managers and other operators and tenants,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our senior living operators' abilities to successfully and profitably operate the communities they manage for us,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The continuing impact of changing market practices on us and our managers and other operators and tenants, such as delayed recovery of the senior housing industry, reduced demand for leased medical office, life science and other space of ours and residencies at senior living communities and increased operating costs,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The financial strength of our managers and other operators and tenants,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Whether the aging U.S. population and increasing life spans of seniors will increase the demand for senior living communities and other medical and healthcare related properties and healthcare services,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Whether our tenants will renew or extend their leases or whether we will obtain replacement tenants on terms as favorable to us as our prior leases,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The likelihood that our tenants and residents will pay rent or be negatively impacted by continuing unfavorable market and commercial real estate industry conditions,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our managers' abilities to increase or maintain rates charged to residents of our senior living communities and manage operating costs for those communities,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to increase or maintain occupancy at our properties on terms desirable to us,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to increase rents when our leases expire or renew,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Costs we incur and concessions we grant to lease our properties,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Risk and uncertainties regarding the costs and timing of development, redevelopment and repositioning activities, including as a result of inflation, cost overruns, tariffs, supply chain challenges, labor shortages, construction delays or inability to obtain necessary permits or volatility in the commercial real estate markets,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to manage our capital expenditures and other operating costs effectively and to maintain and enhance our properties and their appeal to tenants and residents,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to effectively raise and balance our use of debt and equity capital,

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to purchase cost effective interest rate caps,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to comply with the financial covenants under our debt agreements,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to make required payments on our debt,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to maintain sufficient liquidity, including the availability of borrowings under our revolving credit facility, and otherwise manage leverage,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our credit ratings,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to sell properties at prices or returns we target, and the timing of such sales,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to sell additional equity interests in, or contribute additional properties to, our existing joint ventures, or enter into additional real estate joint ventures or to attract co-venturers and benefit from our existing joint ventures or any real estate joint ventures we may enter into,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to acquire, develop, redevelop or reposition properties that realize our targeted returns,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to pay distributions to our shareholders and to maintain or increase the amount of such distributions,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The ability of RMR to successfully manage us,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Competition in the real estate industry, particularly in those markets in which our properties are located,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Government regulations affecting Medicare and Medicaid reimbursement rates and operational requirements,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Compliance with, and changes to, federal, state and local laws and regulations, accounting rules, tax laws and similar matters,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Exposure to litigation and regulatory and government proceedings due to the nature of the senior living and other health and wellness related service businesses,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Actual and potential conflicts of interest with our related parties, including our Managing Trustees, RMR, ABP Trust and others affiliated with them,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Limitations imposed by and our ability to satisfy complex rules to maintain our qualification for taxation as a REIT for U.S. federal income tax purposes,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acts of terrorism, war or other hostilities, outbreaks of pandemics or other public health safety events or conditions, global climate change or other manmade or natural disasters beyond our control, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other matters.

These risks, uncertainties and other factors are not exhaustive and should be read in conjunction with other cautionary statements that are included in our periodic filings. The information contained elsewhere in this Quarterly Report on Form 10-Q or in our other filings with the SEC, including under the caption "Risk Factors", or incorporated herein or therein, identifies other important factors that could cause differences from our forward-looking statements. Our filings with the SEC are available on the SEC's website at www.sec.gov.

You should not place undue reliance upon our forward-looking statements.

Except as required by law, we do not intend to update or change any forward-looking statements as a result of new information, future events or otherwise.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**<u>Statement Concerning Limited Liability</u>**

The Amended and Restated Declaration of Trust establishing Diversified Healthcare Trust, dated September 20, 1999, as amended and supplemented, as filed with the State Department of Assessments and Taxation of Maryland, provides that no trustee, officer, shareholder, employee or agent of Diversified Healthcare Trust shall be held to any personal liability, jointly or severally, for any obligation of, or claim against, Diversified Healthcare Trust. All persons dealing with Diversified Healthcare Trust in any way shall look only to the assets of Diversified Healthcare Trust for the payment of any sum or the performance of any obligation.

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

**PART II. <u>Other Information</u>**

**Item 1A. Risk Factors.**

There have been no material changes to risk factors from those we previously disclosed in our Annual Report.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

*Issuer purchases of equity securities.* The following table provides information about our purchases of our equity securities during the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
|<br><br><br>**Calendar Month** |<br><br>**Number of**<br>**Shares**<br>**Purchased**<sup>(1)</sup> |<br><br>**Average**<br>**Price Paid**<br>**per Share** |<br>**Total Number of**<br>**Shares Purchased**<br>**as Part of Publicly**<br>**Announced Plans**<br>**or Programs** | **Maximum**<br>**Approximate Dollar**<br>**Value of Shares that**<br>**May Yet Be Purchased**<br>**Under the Plans or**<br>**Programs** |
| March 1, 2026 - March 31, 2026 | 12393 | $7.15 |  | $— |
| &nbsp;&nbsp;&nbsp;Total / weighted average | 12393 | $7.15 |  | $— |

---

(1)These common share withholdings and purchases were made to satisfy tax withholding and payment obligations of certain former employees of RMR in connection with the vesting of awards of our common shares. We withheld and purchased these common shares at their fair market values based upon the trading price of our common shares at the close of trading on Nasdaq on the purchase date.

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 3.1 | <u>[Composite Copy of Articles of Amendment and Restatement, dated September 20, 1999, as amended to date. (Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541520000019/dhc063020exhibit31.htm)</u> |
| 3.2 | <u>[Articles Supplementary, dated May 11, 2000. (Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2000.)](https://www.sec.gov/Archives/edgar/data/1075415/000090873700000162/0000908737-00-000162.txt)</u> |
| 3.3 | <u>[Articles Supplementary, dated June 30, 2017. (Incorporated by reference to the Company's Current Report on Form 8-K filed on June 30, 2017.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465917042994/a17-15917_1ex3d1.htm)</u> |
| 3.4 | <u>[Articles Supplementary, dated May 19, 2020. (Incorporated by reference to the Company's Current Report on Form 8-K filed on May 20, 2020.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465920064261/tm2020268d1_ex3-1.htm)</u> |
| 3.5 | <u>[Fourth Amended and Restated Bylaws of the Company, adopted May 31, 2024. (Incorporated by reference to the Company's Current Report on Form 8-K filed on June 4, 2024.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465924068240/tm2416068d1_ex3-5.htm)</u> |
| 4.1 | <u>[Form of Common Share Certificate. (Incorporated by reference to the Company's Current Report on Form 8-K filed on January 2, 2020.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465920000436/tm1926716d1_ex4-1.htm)</u> |
| 4.2 | <u>[Indenture, dated as of December 20, 2001, between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association, as successor trustee to State Street Bank and Trust Company). (Incorporated by reference to the Company's Registration Statement on Form S-3, File No. 333-76588.)](https://www.sec.gov/Archives/edgar/data/1075415/000090873702000007/ex4-1.txt)</u> |
| 4.3 | <u>[Supplemental Indenture No. 7, dated as of July 20, 2012, between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000110465912050176/a12-16695_1ex4d2.htm)[the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000110465912050176/a12-16695_1ex4d2.htm)[5.625% Senior Notes due 2042, including form thereof. (Incorporated by reference to the Company's Registration Statement on Form 8-A filed on July 20, 2012.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465912050176/a12-16695_1ex4d2.htm)</u> |
| 4.4 | <u>[Indenture, dated as of February 18, 2016, between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association). (Incorporated by reference to the Company's Current Report on Form 8-K filed on February 18, 2016.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465916098084/a16-4756_1ex4d1.htm)</u> |
| 4.5 | <u>[First Supplemental Indenture, dated as of February 18, 2016, between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000110465916098084/a16-4756_1ex4d2.htm)[the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000110465916098084/a16-4756_1ex4d2.htm)[6.25% Senior Notes due 2046, including form thereof. (Incorporated by reference to the Company's Current Report on Form 8-K filed on February 18, 2016.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465916098084/a16-4756_1ex4d2.htm)</u> |
| 4.6 | <u>[Second Supplemental Indenture, dated as of February 12, 2018, between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000107541518000010/snh_123117xexhibitx410.htm)[the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000107541518000010/snh_123117xexhibitx410.htm)[4.75% Senior Notes due 2028, including form thereof. (Incorporated by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2017.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541518000010/snh_123117xexhibitx410.htm)</u> |

---

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

---

| | |
|:---|:---|
| 4.7 | <u>[Fourth Supplemental Indenture, dated as of February 8, 2021, among the Company, certain subsidiaries of the Company named therein as guarantors and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000107541521000005/dhc_123120xexhibitx410.htm)[the](https://www.sec.gov/Archives/edgar/data/1075415/000107541521000005/dhc_123120xexhibitx410.htm)[Company's](https://www.sec.gov/Archives/edgar/data/1075415/000107541521000005/dhc_123120xexhibitx410.htm)[4.375% Senior Notes due 2031, including form thereof. (Incorporated by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2020.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541521000005/dhc_123120xexhibitx410.htm)</u> |
| 4.8 | <u>[Supplemental Indenture, dated as of March 5, 2021, among the Company, certain subsidiaries of the Company named therein as guarantors and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000107541521000012/dhc_033121xexhibitx412.htm)[the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000107541521000012/dhc_033121xexhibitx412.htm)[4.375% Senior Notes due 2031. (Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541521000012/dhc_033121xexhibitx412.htm)</u> |
| 4.9 | <u>[Supplemental Indenture, dated as of September 9, 2022, among the Company, certain subsidiaries of the Company named therein as guarantors and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000107541522000031/dhc_093022xexhibitx413.htm)[the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000107541522000031/dhc_093022xexhibitx413.htm)[4.375% Senior Notes due 2031. (Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541522000031/dhc_093022xexhibitx413.htm)</u> |
| 4.10 | <u>[Supplemental Indenture, dated as of November 22, 2022, among the Company, certain subsidiaries of the Company named therein as guarantors and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000107541523000008/dhc_123122xexhibitx415.htm)[the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000107541523000008/dhc_123122xexhibitx415.htm)[4.375% Senior Notes due 2031. (Incorporated by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2022.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541523000008/dhc_123122xexhibitx415.htm)</u> |
| 4.11 | <u>[Supplemental Indenture, dated as of March 1, 2024, among the Company, certain subsidiaries of the Company named therein as guarantors and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to](https://www.sec.gov/Archives/edgar/data/1075415/000107541524000015/dhc_033124xexhibitx416.htm)[the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000107541524000015/dhc_033124xexhibitx416.htm)[4.375% Senior Notes due 2031. (Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541524000015/dhc_033124xexhibitx416.htm)</u> |
| 4.12 | <u>[Supplemental Indenture, dated as of January 16, 2026, among the Company, certain subsidiaries of the](https://www.sec.gov/Archives/edgar/data/1075415/000107541526000013/dhc_123125xexhibitx412.htm)[Company named therein as guarantors and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to the Company's 4.375% Senior Notes due 2031. (Incorporated by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2025.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541526000013/dhc_123125xexhibitx412.htm)</u> |
| 4.13 | <u>[Indenture, dated as of September 26, 2025, between the Company, certain subsidiaries of the Company named therein as guarantors and U.S. Bank Trust Company, National Association, related to the Company's 7.250% Senior Secured Notes due 2030. (Incorporated by reference to the Company's Form 8-K filed on September 29, 2025.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465925094123/tm2526908d1_ex4-1.htm)</u> |
| 4.14 | <u>[Supplemental Indenture, dated as of January 16, 2026, among the Company, certain subsidiaries of the Company named therein as guarantors and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), related to the Company's 7.250% Senior Secured Notes due 2030. (Incorporated by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2025.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541526000013/dhc_123125xexhibitx414.htm)</u> |
| 4.15 | <u>[Registration Rights and Lock-Up Agreement, dated as of June 5, 2015,](https://www.sec.gov/Archives/edgar/data/1075415/000110465915043971/a15-13691_1ex10d4.htm)[among the Company, ABP Trust (f/k/a Reit Management & Research Trust) and Adam D. Portnoy.](https://www.sec.gov/Archives/edgar/data/1075415/000110465915043971/a15-13691_1ex10d4.htm)[(Incorporated by reference to the Company's Current Report on Form 8-K filed on June 8, 2015.)](https://www.sec.gov/Archives/edgar/data/1075415/000110465915043971/a15-13691_1ex10d4.htm)</u> |
| 22.1 | <u>[List of Subsidiary Guarantors. (Incorporated by reference to the Company's](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[Annual](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[Report on Form 10-](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[K](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[for the](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[year](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[ended](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[December](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[3](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[1](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)[, 2025.)](https://www.sec.gov/Archives/edgar/data/1075415/000107541525000033/dhc_063025xexhibitx221.htm)</u> |
| 31.1 | <u>[Rule 13a-14(a) Certification. (Filed herewith.)](dhc_033126xexhibitx311.htm)</u> |
| 31.2 | <u>[Rule 13a-14(a) Certification. (Filed herewith.)](dhc_033126xexhibitx312.htm)</u> |
| 32.1 | <u>[Section 1350 Certification. (Furnished herewith.)](dhc_033126xexhibitx321.htm)</u> |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document. (Filed herewith.) |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. (Filed herewith.) |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. (Filed herewith.) |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. (Filed herewith.) |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. (Filed herewith.) |
| 104 | Cover Page Interactive Data File. (Formatted as Inline XBRL and contained in Exhibit 101.) |

---

------

<u>[**Table of Contents**](#icc333d3079ac4ecbb3cc50e20de4a4bc_7)</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| DIVERSIFIED HEALTHCARE TRUST | DIVERSIFIED HEALTHCARE TRUST |
| By: | /s/ Christopher J. Bilotto |
|  | Christopher J. Bilotto |
|  | President and Chief Executive Officer |
|  | Dated: May 4, 2026 |
| By: | /s/ Matthew C. Brown |
|  | Matthew C. Brown |
|  | Chief Financial Officer and Treasurer |
|  | (Principal Financial and Accounting Officer) |
|  | Dated: May 4, 2026 |

---

## Exhibit 31.1

**Exhibit 31.1**

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)

I, Christopher J. Bilotto, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Diversified Healthcare Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 4, 2026 | /s/ Christopher J. Bilotto |
| | Christopher J. Bilotto |
| | President and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)

I, Matthew C. Brown, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Diversified Healthcare Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 4, 2026 | /s/ Matthew C. Brown |
| | Matthew C. Brown |
| | Chief Financial Officer and Treasurer |

---

## Exhibit 32.1

**Exhibit 32.1**

CERTIFICATION PURSUANT TO 18 U.S.C. SEC. 1350

&nbsp;&nbsp;&nbsp;&nbsp;In connection with the filing by Diversified Healthcare Trust (the "Company") of the Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the "Report"), each of the undersigned hereby certifies, to the best of his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Christopher J. Bilotto |
| Christopher J. Bilotto |
| President and Chief Executive Officer |
| /s/ Matthew C. Brown |
| Matthew C. Brown |
| Chief Financial Officer and Treasurer |

---

Date: May 4, 2026

<br>